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Venereal diseases (VDs) are infections that are mainly transmitted through 
sexual intercourse and amongst these are gonorrhoea, syphilis, chlamydia 
and trichomoniasis. Gonorrhoea is the most commonly known VD and the 
widest spread contagious infection in the world. Out of 448 million cases of 
curable venereal infections, gonorrhoea represents 88 million cases and the 
rest are syphilis, chlamydia and trichomoniasis. Gonorrhoea has recently 
been rated as in the emergent multidrug resistance phase.  
 
Venereal diseases are amongst the major diseases ravaging many rural 
communities. People infected with these diseases are considered a disgrace 
in the community. Indigenous populations, for example the Vha-Venda people 
tend to use medicinal plants to treat these infectious diseases rather than 
using western medicines. Vha-Venda people have depended on medicinal 
plants for their health and survival for millenia. In order to validate and give 
scientific credence to the use of medicinal plants by the Vha-Venda people for 
venereal diseases, several pharmacological assays were carried out. 
 
The study was aimed at evaluating the; antimicrobial, anti-inflammatory 
activities, HIV-type 1 reverse transcriptase (RT) inhibition properties and to 
determine phenolic contents as well as evaluating the mutagenic properties 
of, 12 medicinal plants used by the Vha-Venda people against venereal and 
related diseases. An attempt was also made toward isolating and identification 
of the most active compounds from some extracts that were active against 
Neisseria gonorrhoeae. 
 
Twelve medicinal plants and various plant parts, Adansonia digitata (bark),  
Acacia karroo (bark), Aloe chabaudii (roots), Bolusanthus speciosus (leaves, 
bark and stem), Ekebergia capensis (leaves and bark), Elephantorrhiza burkei 
(roots), Grewia occidentalis (roots), Osyris lanceolata (roots), Pappea 
capensis (leaves), Peltophorum africanum (bark), Pterocarpus angolensis 
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(leaves and bark) and Ximenia caffra (leaves and roots) were evaluated for 
their antimicrobial properties against two Gram-positive (Bacillus subtilis and 
Staphylococcus aureus), three Gram-negative (Neisseria gonorrhoeae, 
Escherichia coli and Klebsiella pneumonia) bacteria and the fungus Candida 
albicans. The plant materials were extracted with petroleum ether (PE), 
dichloromethane (DCM), 80% ethanol (EtOH) and water. Methanol was used 
for extracting materials for phenolic contents and HIV-1RT assays. The Disc 
diffusion method was used to determine gonococcal percentage inhibition and 
a microdilution assay was used to determine minimum inhibition concentration 
(MIC) and minimum fungicidal concentrations (MFC).  
 
Bolusanthus speciosus and X. caffra extracts exhibited the best 
antigonococcal, antifungal and antibacterial activities whilst A. digitata and A. 
chabaudii showed poor activities. The medicinal plants were also evaluated 
for cyclooxygenase (COX-1 and -2) and HIV-1 reverse transcriptase inhibition 
activity. The DCM and PE extracts of A. digitata bark, B. speciosus bark, P. 
angolensis bark and P. capensis leaves showed good anti-inflammatory 
activity against both COX-1 and COX-2. Methanol and water extracts of B. 
speciosus stems, P. africanum bark, P. angolensis leaves and P. capensis 
leaves exhibited good anti-HIV-1 RT activity. A. chabaudii roots, E. capensis 
bark and O. lanceolata roots showed low HIV-1 RT percentage inhibition. 
 
Phytochemical analysis using spectrophotometric methods revealed the 
presence of a variety of phenolic compounds in all the plant extracts including 
total phenolics, flavonoids, gallotannins and condensed tannins. High levels of 
total phenolics, flavonoids, gallotannins and condensed tannins were detected 
in X. caffra. Low amounts of flavonoids, gallotannins and condensed tannins 
were detected in B. speciosus.  
 
The Ames test using Salmonella typhimurium tester strain TA98 with and 
without S9 metabolic activation revealed that all plant extracts were non-
mutagenic toward S. typhimurium strains TA98 without metabolic activation. 
However, E. burkei roots and E. capensis bark showed mutagenic effects 
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toward TA98 after metabolic activation. Therefore, these two plants need to 
be used with caution, however more studies are required to confirm this result. 
 
Good antimicrobial activity observed in X. caffra leaves prompted an attempt 
to isolate active compounds. A pure compound from X. caffra leaves exhibited 
moderate activity (63%) against N. gonorrhoeae. However, the structure of the 
compound has as yet to be ratified.  
 
Pharmacological activity of the twelve medicinal plants used by Vha-Venda 
people against venereal and related diseases were validated in this study. 
The results obtained in this study give credence to the use of some of these 
plants. This study has further confirmed the need for screening these 
medicinal plants for more pharmacological activities. These plants may offer a 
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CHAPTER 1: Introduction and Literature review 
 
1.1. Introduction  
 
Plants have been utilized as a source of medicine for thousands of years and 
continue to play an important role globally in primary health care, mostly in 
developing countries (BALUNAS and KINGHORN, 2005). The use of 
medicinal plants is increasing because people believe they are safe for human 
consumption. There is also an increase in infectious diseases worldwide 
caused by both drug resistance; and lack of sufficient affordable medicine for 
people living in poor communities. The discovery of drugs from medicinal 
plants may be one of the solutions in the fight against infectious diseases.  
Thousands of natural products are in clinical trials and some are already 
confirmed useful in combating some of the diseases. 
 
1.2. Traditional medicine  
 
About 80% of the African population use traditional medicine (TM) to meet 
their health care needs.  Traditional medicine is the only available, accessible 
and affordable source of health care for most people. Traditional medicine is 
considered an important part of the everyday life and well-being in African 
communities. In developed countries, TM is now increasingly being used for 
the treatment and management of chronic diseases (WHO, 2002b).  
 
World health organization (WHO) defines traditional medicine as, ―the sum 
total of knowledge, skills and practices based on the theories, beliefs and 
experiences indigenous to different cultures that are used to maintain health, 
as well as to prevent, diagnose, improve or treat physical and mental illness.‖ 
This includes a diversity of health practices, approaches, knowledge, and 
beliefs incorporating plant, animal and/or mineral based medicines, spiritual 
therapies, manual techniques and exercises, applied singularly or in 
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combination to maintain well-being as well as to treat, diagnose or prevent 
illness (WHO, 2001c; WHO, 2002a).  
 
African Traditional Medicine (ATM) is the oldest and perhaps the most diverse 
of all healing systems (GURIB-FAKIM, 2006). The concept of ATM hinges an 
holistic approach.  It encompass the physical body, mind, emotions and spirit 
that work together to determine good health or ill health, with the interaction 
and relationship between nature, the cosmos and human beings as stated in 
the South African draft national policy on ATM (ATMSA, 2008). In addition, 
other factors are considered in ATM such as  the  existing relations between 
the particular individual and other human beings, both the living, and those 
who have passed away. Therefore the philosophy/religion, psychiatry, 
physiology and biology, are all part and parcel of the conception of ATM 
(ATMSA, 2008). 
 
Due to the availability, accessibility and affordability, there is an increase in 
the appreciation of the role of TM. Traditional medicine has been proven 
effective in cases of ill-health, including mental health, prevention of diseases, 
treatment of non-communicable diseases and improved quality of life in 
elderly people and in persons suffering from chronic diseases (WHO, 2001c). 
 
In 1970, WHO recommended that traditional remedies should be incorporated 
within national drug policies. Increase in commercialization, professionalism 
and pharmaceutical production in ATM especially with medicinal plants known 
to be effective in disease treatment has caused medicinal plants to be 
seriously considered in legislation (WONDERGEM et al., 1989; 
CUNNINGHAM, 1993). There is a growing interest in medicinal plants as 
sources of drugs, due to their promising efficacy and safety such as fewer 
side effects, better patient tolerance and acceptance due to a long history of 
use (VERMANI and GARG, 2002). For several reasons, conventional 
medicine can be inefficient due to side effects and ineffective therapy 
(RATES, 2001). Despite the effectiveness, a large percentage of the world‘s 





1.3. Traditional medicine in South Africa 
 
South Africa has a rich plant biodiversity with an estimated 24 000 plant taxa 
(LOW and REBELO, 1996). Approximately 3000 plant species are used for 
medicinal purposes by an estimated 200 000 indigenous traditional South 
African healers. Up to 60% of the South African population consult one or 
more of the traditional healers in preference to/or in addition to western 
medical doctors especially in rural areas (VAN WYK et al., 2009; MANDER et 
al., 2007).Traditional medicine forms an integral part of the culture of many 
South Africans (VAN STADEN, 2008).  
 
Due to the extensive utilization of TM, many national governments have made 
moves to encourage research into medicinal plants and the development of 
good policies, regulations and trade standards (BODEKER, 2004). In South 
Africa, the government and the National Research Foundation are promoting 
greater interest in research of the country‘s natural plant resources (LIGHT et 
al., 2005). 
 
Medicinal plants work by normalizing the physiological functions of the body 
and by correcting the underlying causes of disorders (MURRAY and 
PIZZORNO, 1999). The advantage of medicinal plants is that they are 
renewable in nature unlike the synthetic drugs that are obtained from non-
renewable sources of basic raw materials such as fossil sources and 
petrochemicals (SAMANTA et al., 2000). Unlike the production of synthetic 
drugs which produces a lot of environmental pollution, the cultivation and 
processing of plants is often environmental friendly (VERMANI and GARG, 
2002). Apart from cultivation, several of the plants used in TM exist in the wild 
and are locally available, especially in developing and underdeveloped 
countries (VERMANI and GARG, 2002). Some research findings have 
resulted in the isolation and identification of important natural products. To 
date numerous publications on healing and pharmaceutical values of 
medicinal plants have been documented (MATHEKGA et al., 2000; 




1.4. Drug discovery from medicinal plants 
 
Antimicrobial resistance is a natural biological phenomenon which was 
recognized first as a scientific curiosity and then as a threat to the effective 
treatment of most microbial infections (WHO, 2001b). The CIA (1999) 
described drug resistance by microbial organisms as a threat to global stability 
and the national security of the United States of America.  
 
 The discovery of the healing power of medicinal plants began during ancient 
times. About 25% of the drugs prescribed worldwide come from plants 
(BALANDRIN et al., 1993). It is also acknowledged that 121 active 
compounds that are being used as medicinal drugs are derived from plants. 
Of the 252 drugs considered as basic and essential medicine by WHO, 11% 
are exclusively of plant origin and a significant number are synthetic drugs 
whose chemical structures were obtained from natural precursors (RATES, 
2001). Approximately one quarter of the best selling drugs in 2001 and 2002 
were natural products or derived from natural products (BUTLER, 2004).  
 
In 1980 prescription drugs derived from plants contributed $8 billion to the 
American economy (BALANDRIN et al., 1993; FARNSWORTH et al., 1985). 
In China 7295 plant species are utilised as medicinal agents (MAHIDOL et 
al., 1998). In a study of the top 150 proprietary drugs used in the USA (1993), 
it was reported that 57% of them contained at least one major active 
compound derived from biological sources (PATWARDHAN, 2009). It is 
estimated that only 5 to 15% of the 250, 000 existing species of higher plants 
have been systematically surveyed for the presence of biologically active 
compounds (BALANDRIN et al., 1993). It is estimated that 60% of anti-
tumour and anti-infectious drugs already on the market or under clinical trial 
are of natural origin (SHU, 1998; YANIV and BACHRACH, 2005).  
 
The screening of medicinal plants for biological activity has resulted in the 
isolation of active compounds from the early 19th century when morphine was 
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isolated from Papaver somniferum by the German pharmacist Friedrich 
Sertϋner in 1805 (KINGHORN, 2001; BALANDRIN et al., 1993). The success 
of morphine isolation led to the identification of many other drugs such as 
quinine from Cinchona spp, codeine from Papaver somniferum, atropine from 
Atropa belladonna, reserpine from Rauvolfia serpentina and digoxin from 
Digitalis species (VAN WYK et al., 2009). The majority of the compounds are 
still in clinical use today. Other important plant-derived drugs include arteether 
for the treatment of malaria, galantamine for the treatment of Alzheimer‘s 
disease (AD), nitisinone for the rare inherited disease (tyrosinaemia) and 
tiotropium for the treatment of chronic obstructive pulmonary disease 
(BALUNAS and KINGHORN, 2005).  
 
According to BALUNAS and KINGHORN (2005), drugs derived from 
medicinal plants can serve not only as new drugs but also as templates for 
synthetic drug development by chemists. Therapeutics derived from plants are 
usually less specific and can affect more than one molecular target and can 
be helpful in complex disorders in which the causes are not known. However, 
in some cases these drugs are not the first choice for treating severe and life-
threatening diseases, but they can be useful in many other instances (VAN 
WYK and WINK, 2004). 
 
1.5. Venereal diseases 
 
The human body is extremely complex and if one element is missing or not 
performing optimally, because of genetic or environmental influences 
(infections by bacteria, parasites, fungi, viruses, burns, wounds, toxins from a 
diet that modulate the activity and function of proteins in the body), it results in 
health disturbances (VAN WYK and WINK, 2004).  
 
Sexually transmitted diseases (STDs), also known as sexually transmitted 
infection (STIs), or venereal disease (VDs), are caused by bacterial, viral and 
parasitic pathogens, some of which are listed in Table 1. In this thesis, the 
abbreviation VDs will be used. These pathogens are mainly transmitted, 
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through sexual intercourse. Transmission can occur occasionally through 
other nonsexual means such as mother to child contract during pregnancy, 
lactation and childbirth, and through blood transfusions or tissue transfer 
(WHO, 2006). Some VDs increases the chances of infection with the deadly 
or incurable pathogens which may results in AIDS and genital herpes 
(WASSERHEIT, 1992). About 26% of deaths occurring in South Africa in 






Table 1: Venereal diseases and the organisms responsible for the infection   
ORGANISM DISEASE 
BACTERIA  
Neisseria gonorrhoea Gonorrhoea 
Treponema pallidum Syphilis 
Haemophilus ducreyi Chancroid 
Gardnerella vaginalis Bacterial vaginosis 
Chlamydia trachomatis Chlamydia infections, Lymphogranuloma venereum 
Mycoplasma hominis Postpartum fever, salpingitis 
Calymmatobacterium 
granulomatis  
Donovanosis (granuloma inguinale) 
Shigella sp.  Shigellosis in homosexual men 
Campylobacter sp Enteritis, proctocolitis 
Group B Streptococcus Neonatal sepsis, neonatal meningitis 
VIRUSES  
Human immunodeficiency 
virus (HIV)  





Table 1: continuation 
VIRUSES  
Herpes simplex virus Initial and recurrent genital herpes, aseptic meningitis, neonatal herpes, cervical dysplasia and 
carcinoma, carcinoma in situ of the vulva 
Hepatitis B virus Acute hepatitis B, chronic active hepatitis, persistent (unresolved) hepatitis, polyarteritis nodosa, chronic 
membranous glomerulonephritis, mixed cryoglobulinemia, polymyalgia rheumatic, hepatocellular 
carcinoma 
Hepatitis A virus Acute hepatitis A 
Cytomegalovirus Heterophil-negative infectious mononucleosis, congenital infection, gross birth defects and infant 
mortality, cognitive impairment, cervicitis, protean manifestations in the immunosuppressed host. 
Molluscum 
contagiosum virus 
Genital molluscum contagiosum 
Human papillomavirus 
(HPV) 
Genital (venereal) warts 
PARASITES  
Trichomonas vaginalis  Trichomonal vaginitis 
Giardia lambia Giardiasis in homosexual men 





Table 1: continuation 
FUNGI     
Candida albicans Vaginal yeast infections    
ECTOPARASITES     
Phthirius pubis  Pubic lice    
Sarcoptes scabiei Scabies    





1.5.1. Prevalence of venereal diseases   
 
More than 340 million infections with VDs occur globally every year.  These 
are mainly the curable VDs such as syphilis, gonorrhoea, chlamydia and 
trichomoniasis in age groups between 15 and 50 years (WHO, 2001a). The 
percentages of seventy five to eighty five of these cases occur in developing 
countries (MAYAUD and MABEY, 2004). South-east Asia is the largest 
region with the highest cases of VDs followed by sub-Saharan Africa, Latin 
American and the Caribbean (WHO, 2001a). Apart from sexual transmitted 
bacteria and protozoa infections, high rates of viral STIs also occur yearly 
such as HIV, HPV, Herpes simplex virus type 2 and Hepatitis B virus (WHO, 
2006). According to MAYAUD and MABEY (2004) these infections constitute 
a huge health and economic burden globally, with 17% of economic losses 
caused by ill-health especially in developing countries. Industrialized nations 
can also be expected to experience an increase in the burden because of the 
prevalence of non-curable viral infections, irresponsible trends in sexual 
behaviour and increased migrations of the economically active populations 
(WHO, 2006). Cervical cancer which is causes by HPV also forms part of the 
STIs in Southern Africa. Over 98% of the deadly VDs occur as HIV/AIDS 
(JOHNSON et al., 2008). 
 
1.5.2. Effect of untreated venereal diseases 
 
Untreated VDs result in life threatening conditions. Syphilis results in 25% of 
stillbirth and 14% of neonatal death with an overall perinatal mortality of about 
40%. In Africa syphilis prevalence in pregnant women ranges from 4 to 15% 
(WHO, 2006). On the other hand, 35% of untreated gonococcal infections 
results in pelvic inflammatory disease. Up to 50% of infants born with 
untreated gonorrhoea and chlamydial infection usually develop ophthalmia 
neonatorum, which can lead to blindness. Almost 4000 new-born babies 





Herpes simplex virus type 2 is the leading cause of genital ulcers mostly in 
women (WHO, 2006). It also plays an important role in the transmission of 
HIV (WHO, 2006). Results of a study in Mwanza (United Republic of 
Tanzania) by DEL MAR PUJADES RODRÍGUEZ et al. (2002) showed that 
74% of HIV infections in men and 22% in women could be attributable to the 
presence of Herpes simplex virus type 2. Human papillomavirus cause about 
500 000 cases of cervical cancer annually with 240 000 deaths in developing 
countries. It is estimated that Hepatitis B virus results in 350 million cases of 
chronic hepatitis and at least one million deaths each year (WHO, 2006). In 
the same report WHO (2006) states that the population at risk for STIs will 
continue to grow dramatically.   
 
Sexually transmitted infections are a threat to public health. They are a major 
problem in most parts of the world, mostly in developing countries where the 
infections constitute a huge health and economical burden. Educating and 
monitoring infected people is one of the major issues especially in resource-
poor countries where the treatment for sexual infections face numerous 
problems such as stigmatization and mistreatment because of lack of trained 
personnel (WHO, 2006). 
 
1.6. Overview of medicinal plants used on venereal diseases 
 
Numerous studies on plants that are used to treat conditions related to VDs 
have been performed (MEKKAWY et al., 1995; MATSUSE et al., 1999; 
VLIETINCK and BERGHE, 1991; KAMBIZI and AFOLAYAN, 2001; 
RAJBHANDARI et al., 2001; VERMANI and GARG, 2002; NDUBANI and 
HÖJER, 1999; DE WET et al., 2011). Over 80 references in southern Africa 
relate to medicinal plants used to treat VDs (VERMANI and GARG, 2002). 
However, only a few of the studies have focused on the bacterial pathogens 
associated with VDs (KAMBIZI et al., 2004; TSHIKALANGE et al., 2005; 
BUWA and VAN STADEN, 2006; TSHIKALANGE et al., 2008; 
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FERNANDES et al., 2008; KAMBIZI and AFOLAYAN, 2008; KLOS et al., 
2009; VAN VUUREN and NAIDOO, 2010).  
 
Nine plants that are used globally for the treatment of STIs were recorded by 
DE WET et al. (2011) namely: Bridelia cathartica subsp. cathartica, 
Cladostemon kirkii, Erianthemum dregei, Euphorbia hypericifolia, Ipomoea 
batatas, Krauseola mosambicina, Mimusops caffra, Opuntia stricta and 
Sarcophyte sanguinea subsp. sanguinea. Three of the above mentioned 
plants (E. hypericifolia, I. batatas and O. stricta) are naturalized exotics in 
South Africa, (DE WET et al., 2011). The use of medicinal plants for 
symptomatic treatment of VDs dates back at least to 1574 when Smilax 
officinalis was first introduced for the treatment of syphilis in Europe 
(VERMANI and GARG, 2002).  
 
According to GREEN (1992) the majority of people in sub-Sahara Africa 
believe that TM used for treating sexual transmitted infection is more effective 
than western medicine. This can be mainly because of stigmatization that is 
associated with VDs. Particularly women are reluctant to disclose information 
related to their genitals, thus they find it better to seek help from traditional 
healers (KAMATENESI-MUGISHA et al., 2008).  
 
1.7. Venda people and traditional medicine 
 
All cultures have some definable people with plant knowledge that includes 
appropriate edible plants, medicinal plants and ceremonial plants (CSEKE et 
al., 2006). 
 
The Venda community is one of the remote tribes in South Africa. The Venda 
people (Vha-Venda), reside in the Limpopo province, in the upper North of 
South Africa bordering Zimbabwe and Mozambique. Limpopo province has a 
population of 5.3 million. The province is divided into five districts (Vhembe, 
Mopani, Capricorn, Sekhukhune and Waterberg). The study area for the work 
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described in this thesis was done in Vhembe district which falls under the 
Venda region.  
 
Venda people have depended on the natural environment for their health and 
survival for ages. The dependence continued with modifications up until the 
19th century, when civilization with it inherent Christian nature challenged its 
credibility particularly with respect to the medicinal, magical, ritual and 
religious aspects that are part of it (MABOGO, 1990). 
 
The Vha-Venda culture does not differ much from other cultures in South 
Africa such as the Zulu culture. They believe in traditional healers and the use 
of traditional medicine for their health needs. The Vha-Venda uses a variety of 
plant parts, such as leaves, bark and roots in their TM. The plant materials 
may be combined with animal fats, bones, organs such as brains, intestines, 
or genitals to make stronger medicines (HANISCH, 2002).  
 
1.7.1. Traditional healing by Vha-Venda 
 
The knowledge of medicinal plants in the Venda culture is obtained from the 
forefathers or through spirit mediums from their ancestors and is subsequently 
passed through generations. The knowledge of using medicine is limited to 
those who are brought up in traditional Venda culture. Simple plants are used 
as medicine for common ailments such as colds, diarrhoea, colic, most sexual 
transmitted diseases, treatment of wounds, toothache and sore eyes 
(MABOGO, 1990).  
Among the Vha-Venda, health providers are distinguished as specialists in 
certain fields of medicinal practice. Such people may be referred to as 
traditional practitioners (herbalist), diviners or magicians. Traditional 
practitioners (ňangas) specialize in the use of herbs in treating various 




A traditional practitioner is an individual who is recognized by the community 
as competent in health care (PRETORIUS, 1999).  The traditional healer can 
also be regarded as a technician and diagnostician (L’ABBE, 2005). Among 
these practitioners, are those who specialize in children‘s diseases, women‘s 
fertility problems, and incurable ulcers related to cancer, or sexually 
transmitted diseases. There are many others who claim to treat all diseases, 
without being specific (MABOGO, 1990). 
Diviners (mungome) are people who normally do not treat diseases but who 
use their divinatory powers to determine cause and source of people‘s health 
and social complaints (generally divination dice which are made of bones 
and/or wood are use for this purpose) (MABOGO, 1990). Divination involves 
casting of objects, including bones, mediumistic ability (contact with the 
ancestors), or dreams and visions. Treatment may also involve ritual sacrifice 
to appease the ancestors, ritual and magical strengthening of people and 
possessions, steaming, purification, sniffing of substances, wearing charms, 
cutting and piercing of human flesh (PRETORIUS, 1999). Some of the 
Diviners do not use the dice but they use other processes including Fembo 
(the use of smelling substances).  
Magicians, specialize in natural objects, usually plants and animal products, to 
produce healing effects. Magicians thus mainly cure people who are suffering 
from conditions mainly caused as a result of bewitchment (MABOGO, 1990). 
However, some practitioners combine some or all of the specialized fields, 
thus making it difficult to differentiate between them (MABOGO, 1990).  
Just like in many other communities of South Africa, traditional healers are 
important in the Vha-Venda culture as they provide the first line of health care 
to the people especially in rural areas (SAMIE et al., 2005). 
There are many ways which place traditional healers in respectable positions 
when compared to alternative mainstream health providers. These include 
availability, accessibility, their familiarity with culture bound syndromes, 
traditions, and relationships with patients. Some of the reasons are the lack of 
trust in western medical practitioners to effectively treat psychosocial 
15 
 
problems and beliefs that illnesses arises from supernatural causes and 
displeasure of ancestral gods or evil spirits (KGOATIA, 1997).  
 
1.7.2. Venda medicinal plants 
 
About 151 medicinal plant species are found in the Venda district of which 25 
species are used to treat venereal diseases (ARNOLD and GULUMIAN, 
1984; DE WET et al., 2011). Out of 25 species that are used for venereal 
disease, Alibizia anthelmintica and Alibizia versicolor are most preferred (DE 
WET et al., 2011). Approximately 69 medicinal plants are traded in Venda 
(TSHISIKHAWE, 2002). Some of the traded plants are threatened and these 
include Brackenridgea zanquebarica and Warburgia salutaris (MOENG and 
POTGIETER, 2011).   
 
The use of medicinal plants is popular because of African traditions which 
allow people to explore the diverse plant resources that surround them (VAN 
VUUREN, 2008). The parts of specific medicinal plants are collected during 
the favorable harvesting season, dried by directly exposing them to sunlight, 
ground using mortar and pestle and then stored in containers in powdered 
form for future usage (SAMIE et al., 2010). The parts of the plant used vary 
among species and with traditional healer. It also depends on the nature and 
state of the disease (MABOGO, 1990). The whole plant is used for ritual 
purification (u bvisa tshinyama) (MABOGO, 1990). Few medicinal plants used 
by Vha-Venda people have been reported for antimicrobial activities (OBI et 
al., 2003; STEENKAMP et al., 2007a and 2007b; PALLANT and 
STEENKAMP, 2008; FERNANDES et al., 2008 and GREEN et al., 2010).  
 
1.7.3. Conservation of Venda medicinal plants  
 
In Venda, medicinal plants are conserved via the system which is enforced by 
the chief and headmen. The system is primarily aimed at protection and 
preservation of those plants that are important sources of food or medicine 
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such as Sclerocarya birrea, Parinari curatellifolia, Adansonia digitata, and 
Boscia albitrunca (MABOGO, 1990).  
 
1.8. Aims and objectives 
 
Venereal diseases continue to be a public health concern globally, mostly in 
South Africa where transmission rate is increasing. In rural areas, infected 
people do not want to visits public health institutions because of the stigmas 
attached to VDs. Venereal diseases are considered a disgrace in the 
community. The unprecedented emergence of drug resistance against 
pathogens that causes VDs has complicated the treatment of the infections. 
Because of these complications, there is a necessity to search for new 
antimicrobial substances from various sources.  
 
Medicinal plants have proved to be a source of safer treatments for many 
diseases. This study aims at evaluating the pharmacological properties of 
twelve medicinal plants used by the Venda people for treating venereal and 
related diseases. This was achieved by testing the medicinal plants in various 
pharmacological tests. These tests include the antimicrobial bioassays 
(antibacterial, antifungal and antigonococcal) and enzyme inhibition bioassays 
[cyclooxygenases enzymes (involved in anti-inflammatory) and HIV-1 reverse 
transcriptase (RT)]. Determination of phenolic compounds was also carried 
out. Genotoxicity of the plant extracts was also evaluated to test for safety of 
the plants. The information obtained from this study could go a long way in 
validating the use of the plants by the Venda people and offer scientific 
credence to the ideas of integrating such plants in health care systems which 
in turn will be helpful to the rural communities. An attempt was also made 
toward isolating and identification of the most active compounds for some 








1.9. Plant selection 
 
The selection of plants used in this study was based on the literature of plants 
used by Vha-Venda people for VDs and related diseases using the thesis of 
MABOGO (1990) as a guide. Table 2 lists the plants used in the study. The 
plants were collected from Vhembe district and voucher specimens (voucher 
numbers provided in Table 2) were deposited in the Bews Herbarium at the 


















Muvhuyu Bark Mulaudzi 
28 NU 
Venereal diseases. 
Urinary disorders and 
mild diarrhoea  
Anti-inflammatory, anti-pyretic and analgesic 
agents (RAMADAN et al., 1994; PALOMBO, 
2006; AJOSE, 2007; KARUMI et al., 2008), 
antibacterial, antiviral and anti trypanosomal 
activities (ANANI et al., 2000; HUDSON et al., 
2000; ATAWODI et al., 2003; 











inflammation of eyes 
and emetic.  
Crude extract have  rich in proanthocyanidin 
and flavonols (DUBE et al., 2001), anti-
inflammatory and analgesic activity (ADEDAPO 
et al., 2008) 
Asphodelaceae 
Aloe chabaudii 
var. chabaudii  
















Part used Voucher 
number 












Cleaning blood, kidney 
problems, and venereal 
diseases. 
Antibacterial activity (BOJASE et 
al.,  2002; ERASTO et al., 2004) 
Meliaceae 
Ekebergia 





Chronic cough, emetic, 
backache, headache, 
dysentery and skin diseases.   
Uterotonic , antispasmodic activity  
(VAN WYK et al., 2009; SEWRAM 
et al., 2000),  antibacterial activity 








Venereal diseases, cleaning of 
body systems, regulation of 
menstruation, aphrodisiac, and 
miscarriage. 
 
Abortifacient (ARNOLD and 
GULUMIAN, 1984; HUTCHINGS 
et al., 1996;WATT and BREYER-
BRANDWIJK, 1962), antibacterial 













Part used Voucher 
number 





Mulembu Roots Mulaudzi 
14 NU 
Venereal diseases, bladder 
ailments. 




Hochst. & Steud.  
 
Mpeta Roots Mulaudzi 
16 NU 
Venereal diseases, styptic effects 
on wounds, menorrhagia and 
infertility. 
Antibacterial and antifungal activity 




Eckl. & Zeyh   
Mulilwe Leaves Mulaudzi 
17 NU 
Venereal diseases, painful eyes 
and aphrodisiac. 
Use to control snail (Biomaphalaria 
pfeifferi) that causes Schistosomiasis 









Table 2: continuation 
Family 




Part used Voucher 
number 
Traditional uses Biological activities 
Fabaceae 
Peltophorum 
africanum Sond  
 
Musese Bark Mulaudzi 
18 NU 
Cold, fever, sore throat, sore, 
ulcer, blisters in the oral 
cavity, stomach complaints 
and wounds. 
Antibacterial and antioxidant activity 
(BIZIMENYERA et al., 2005; 
STEENKAMP et al., 2007a), anti-HIV  
activity (BESSONG et al., 2005), 
antihelimetic activity (BIZIMENYERA et 
al.,  2006) 
Fabaceae 
Pterocarpus 
angolensis DC  
 




Venereal diseases, piles, 
amenorrhoea, haematuria 
and bilharzias. 
Antibacterial  activity (LUSEBA et al., 









Venereal diseases, blood in 
faeces, diarrhoea, fever, 
menorrhagia, febrifuge, 
cough, infertility, headache, 
menorrhagia, eye sickness, 
indigestion and scurvy. 
Antibacterial  activity (SAMIE et al ., 
2005; MATHABE et al., 2006), 
antifungal activity (FABRY et al., 1996) 
and antidiarrhoeal activity (HUTCHINGS 








Infectious diseases are the second leading cause of death worldwide, and the 
third leading cause of death in developed countries in both children and 
adults. The burden of infectious diseases falls most heavily on people in 
developing countries by causing morbidity and mortality (FAUCI, 2001; 
HAMBURG, 2008). In developed countries, infectious disease mortality 
disproportionately affects indigenous and disadvantaged minorities 
(GUERRANT and BLACKWOOD, 1999; BUTLER et al., 2001). Of the 
approximately 57 million annual deaths worldwide, 15 million (>25%), are 
estimated to be related directly to infectious diseases (MORENS et al., 2004).  
Infectious diseases are caused by viruses, bacteria, fungus, and parasites 
which results in respiratory infections, HIV/AIDS, diarrhoeal diseases, 
tuberculosis, malaria, STDs (other than HIV), meningitis, Hepatitis B and C, 
tropical parasitic diseases and Dengue (MORENS et al., 2004).  
 
In the twentieth century, antimicrobial therapies, especially antibiotics for 
bacterial diseases (e.g. pneumonia) and anti-parasitic drugs (e.g. malaria) 
have been successful against infectious diseases. However, during the same 
era, there was the discovery of antimicrobial resistance followed by an 
increase in disease transmission and a decline in the development of new 
antibiotics (COHEN, 1992; 2000). This led to the emergence of multidrug-
resistance which has created a situation in which there are few or no 
treatment options for infections with certain pathogenic bacteria (WENZEL 
and EDMOND, 2000). To prevent and control infectious diseases it is of vital 
interest and concern in both developed and developing countries to come up 
with new remedies for such diseases (HAMBURG, 2008). New antimicrobial 
agents with different modes of action against bacterial, fungal, parasite and 






2.1.1. Bacterial infections  
 
Bacteria are widely distributed and the most abundant group of unicellular 
organisms on earth, capable of adapting in a diverse range of environments 
such as in soil, water and air. They are both useful and harmful to humans. 
Many parasitic bacteria do not harm their hosts. Some cause disease by 
producing poisons. Bacteria have a prokaryotic cell type with a rigid wall which 
protects the cell against osmotic damage. The structure of the cell wall differs 
in Gram-positive and Gram-negative bacteria (SLEIGH and TIMBURY, 1998).  
 
Gram-negative bacteria differ from Gram-positive by the presence of an outer 
membrane composed of lipopolysaccharides. It also contains specific proteins 
for transporting hydrophilic molecules. Other proteins are receptor sites for 
phages and bacteriocins. The outer membrane in Gram-negative bacteria 
covers the peptidoglycan layer, which is attached to the outer membrane by 
lipoproteins. The layer is separated by periplasm from the cytoplasmic 
membrane. Gram-positive bacteria have more peptidoglycan layers with no 
periplasm (SLEIGH and TIMBURY, 1998). 
 
There are many bacteria that are known to cause VD, one such bacterium is 
Neisseria gonorrhoeae. Neisseria gonorrhoeae is a common cause of VD. It is 
responsible for causing gonorrhea. Gonorrhea is one of the most common 
VDs in developing countries and is now a major public health concern 
worldwide (WHO, 2011).   
 
Neisseria gonorrhoeae is a Gram-negative diplococcus. It is found in humans 
and highly adapted to survive in the genital tract. Neisseria gonorrhoea is 
known to have existed for the past 3500 to 4000 years and was first described 
by Albert Neisser in 1879 (KRUGER and BOTHA, 2007). Gonorrhea is mostly 
spread through sexual contact. It is associated with a significantly increasing 
HIV transmission (TAPSALL, 2001). Untreated infections may lead to serious 
complications including sterility, pelvic inflammatory diseases and ectopic 
pregnancy (RUDDOCK et al., 2011). This pathogen thrives in warm, moist 
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dark areas of the human body including the genitals, anus and mouth. It 
produces a variety of co-infection with common pathogens such as 
Escherichia coli, Staphylococcus saprophyticus, Proteus mirabilis, Klebsiella 
pneumoniae, and Enterobacter species (ISMAIL, 1999; BUWA and VAN 
STADEN, 2006).  
 
Statistically, gonorrhoea is one of the most wide spread contagious infections 
in the world (KRUGER and BOTHA, 2007). It was estimated by WHO in 1995 
that 62 million cases of gonorrhoea were recorded in Asia, sub-Saharan Africa 
and South Central America (TAPSALL, 2001) and 62.35 million cases 
occurred in 1999, affecting more women than men (WHO, 2001a). To date it 
is estimated that globally, out of approximately 448 million new cases of 
curable VD, gonorrhoea represent 88 million cases and the rest are syphilis, 
chlamydia and trichomoniasis (WHO, 2011). In Africa, studies have shown 
that 3.1% of pregnant women are infected with gonorrhoea in Angola, 
Cameroon, Chad, Democratic Republic of Congo, Equatorial Guinea, Gabon 
and 7.8% in South Africa (WHO, 2001a).  
 
Gonorrhoea is still a common VD in South Africa with about 36-68% 
prevalence at STD clinics. It is difficult to control gonorrhoea because of the 
resistance of the pathogen to antibiotics (KRUGER and BOTHA, 2007). 
TAPSALL (2001) suggested that the control of gonorrhoea, including other 
VD, requires a complex and comprehensive strategy that integrates 
education, counselling, diagnosis, treatment and case-finding, though the 
ability to control the disease is limited by the significant proportion of infections 
that remain undiagnosed.  
 
Bacillus subtilis is a rod shape endospore-forming Gram-positive bacterium 
that occurs in chainlike formations. Its primary habitat is the soil and is 
responsible for food poisoning (RYAN and RAY, 2004). Staphylococcus 
aureus is a spherical Gram-positive parasitic bacterium that causes illnesses 
ranging from minor skin infections and abscesses, to life-threatening diseases 
such as pneumonia, meningitis and septicemia (LOWY, 1998). Escherichia 
coli is a Gram-negative bacterium normally present in the intestinal tract of 
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humans and other animals. Escherichia coli can sometimes be pathogenic, 
thus posing a threat to food safety, causing diarrhoea, wound and urinary 
infections (SLEIGH and TIMBURY, 1988). Klebsiella pneumoniae belongs to 
a genus of non-motile, rod-shaped Gram-negative enterobacteria which 
causes pneumonia, urinary tract infections, bacteremia, septicaemia, chronic 
pulmonary disease, soft tissue infections, diarrhoea and other infections 
(RYAN and RAY, 2004; HARYANI et al., 2007).  
 
2.1.2. Fungal infection 
 
Besides bacterial infections, human are also fighting fungal infection. Fungal 
infections are associated with increasing morbidity and mortality in 
immunocompromised and severely ill patients (LEHRNBECHER et al., 2010) 
as well as complications in cancer patients (MARTINO and GIRMENIA, 
2000). However, a few fungal pathogens are causative agents of infectious 
diseases, for example, Candida albicans.  
 
Candida albicans (a form of yeast) is the major causative agent of fungal 
infections (ROHITASHW and SHUKLA, 2010). It is capable of causing 90% 
of fungal infections by colonizing the mucosal surface of the gastrointestinal 
tract, female genital tract and infects the skin and mucous membranes of the 
vagina (vaginitis), head of the penis (balanitis), mouth (oral thrush) or rectum 
(CHAITOW, 1996; RYAN and RAY, 2004; MURRAY and PIZZORNO, 1999). 
Overgrowth of C. albicans results in Candidiasis mostly in patients with 
endocrine disorder, immunosuppression, malignant disorders, HIV and AIDS 
(MARTÍNEZ et al., 1998). Ninety percent of HIV/AIDS patients suffer from 
fungal infections and 20% of them die as a direct consequence of such 
infections (CHAITOW, 1996).  
 
2.1.3. Antibiotic resistance of bacterial and fungal infection 
 
Many drugs are available for the treatment of microbial infections, but some 
microbial have led the development of resistance and side effects. Neisseria 
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gonorrhoea strains have developed a high level of resistance to several 
antibiotics, including penicillin, tetracycline,.quinolones, cotrimoxazole, 
sulphonamides, macrolide, mostly in regions of the world where gonorrhoea is 
highly prevalent (WHO, 2011; TAPSALL, 2001; DOH, 2008). Some of these 
antibiotics are currently not recommended for the treatment of gonorrhea in 
the majority of countries in the world such as penicillin, tetracycline and 
quinolones (WHO, 2011). Staphylococcus aureus has sequential emergences 
of resistance. In 1940s it was resistant to sulpha drugs, followed by penicillin 
in 1950s then methicillin in the 1980s and recently it was reported to be 
resistant to vancomycin (CDC, 2002). Escherichia coli in some hospital 
patients in United States of America and UK have shown resistant to 
sulphonamide and ampicillin-sulbactam (ENNE et al., 2001; KAYE et al., 
2000). Klebsiella pneumoniae including other Klebsiella species are resistant 
to celphalosporin β-lactam antibiotics (BRADFORD et al., 1997; RAHAL et 
al., 1998; KEYNAN and RUBINSTEIN, 2007).  
 
There are number of effective antifungal agents available for treatment of 
various forms of fungal infections, for example amphotericin B (AmpB), azole, 
fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, 
micafungin and anidulafungin, but they are very limited in supply. 
Nevertheless, the widespread and incorrect use of these antifungal agents 
has led to the emergence of drug resistance in several commom pathogenic 
fungi, a major challenge in the treatment of these diseases (GRAYBILL, 
1996). Acquired resistance to AmpB in C. albicans has been reported along 
with azole and fluconazole resistance. Very little information on AmpB 
resistance to C. albicans is available. Candida lusitaniae and C guilliermondii 
frequently develop resistance to AmpB (VIVIANI et al., 1998; KRCMERY and 
BARNES, 2002). Several antifungal drugs were recently approved, but 
systemic fungal infections still remain fatal (FOULKES, 2001). 
 
The high prevalence of antibiotic resistant is due to a number of factors such 
as inappropriate or inadequate antibiotic therapy, selective pressure and a 
high prevalence of other diseases coupled with lack of capacity to initiate 
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surveillance or prevention programs (RUDDOCK et al., 2011). With the 
emergency of single and multidrug resistance, alternative effective treatments 
of bacterial and fungal infections are urgently needed, with the agents that 
can target or inhibit infections including co-infections. Therefore, development 
of antimicrobial agents from natural products could play an important role in 
meeting the demand for new drugs against microbial infections.  
 
In the search for new natural plant-derived antimicrobial agents, twelve 
medicinal plants used by the Venda people against venereal diseases were 
evaluated against five infectious bacteria including two Gram-positive (B. 
subtilis and S. aureus), three Gram-negative (N. gonorrhoeae, E. coli and K. 
pneumoniae) bacteria and a fungus C. albicans using the disc-diffusion assay 
for antigonococcal activities and microdilution techniques for antibacterial and 
antifungal activities.  
 
2.2. Materials and Methods 
 
2.2.1. Plant collection and sample preparation 
 
Plant materials were collected from Limpopo province (Venda, Tshiendeulu 
mountain, Mandiwana village: 22°85´34.57˝ S, 30°141´65.6˝ E South Africa. 
Voucher specimens were deposited in the Herbarium at the University of 
KwaZulu-Natal, Pietermaritzburg. Plant materials were dried at 50 °C for 3 
days, ground and stored in airtight containers under dark conditions at room 
temperature. 
 
2.2.2. Preparation of plant extracts 
 
Dried, ground plant materials were extracted sequentially with 20 ml/g of 
petroleum ether (PE), dichloromethane (DCM), 80% ethanol (EtOH) and water 
with sonication (Julabo GMBH, Germany) on ice for 1 h. The organic extracts 
were filtered under vacuum through Whatman No. 1 filter paper and 
concentrated under vacuum using a rotary evaporator (Rotavapor-R, Buchi, 
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Switzerland) at 35 °C. Water extracts were collected into glass jars and freeze 
dried. The concentrated organic extracts were transferred into sample vials 
then dried at room temperature under a stream of cold air. The dried extracts 
were kept in airtight glass sample vials at 10 °C in the dark until required for 
the different assays. 
 
2.2.3. Antigonococcal assay 
 
2.2.3.1. Preparation of Neisseria gonorrhoeae for stock and storage  
 
Neisseria gonorrhoeae (ATCC 49226) was obtained from ATCC as KWIK-
STIKTM plus Microorganism. The bacteria were inoculated onto chocolate agar 
(Oxoid GC agar base) supplemented with 2% (W/V) of haemoglobin and 1% 
(v/v) of Vitox supplement and incubated for 24 h at 37 °C in 5% CO2. From the 
overnight culture, colonies were suspended in Mueller-Hinton broth (MH 
broth) with 20% glycerol to break the clumps, the mixture was vortexed. One 
millilitre of the mixtures was pipetted to cryo tubes for long term storage and 
stored at -70 °C. 
 
2.2.3.2. Disc diffusion bioassay 
 
The stored bacteria ( -70 °C) were inoculated onto chocolate agar (Oxoid GC 
agar base) supplemented with 2% (W/V) of haemoglobin and 1% (v/v) of Vitox 
supplement and incubated for 24 h at 37 °C in 5% CO2. Four to five colonies 
of pure culture from overnight culture were suspended in 5 ml of MH broth. 
The turbidity of the cell suspension at 450 nm was adjusted by adding MH 
broth or organism as required, until the turbidity of the suspension was 
equivalent to the turbidity of a 0.5 McFarland BaSO4 standard to the 
equivalent of 108 CFU/ml. 
 
Gonococcal activity of the 12 medicinal plant crude extracts was determined 
by disc diffusion (RINGERTZ et al., 1991; PUTNAM et al., 1992). Crude plant 
extracts were dissolved in dimethylsulfoxide (DMSO) to  a  concentration of 50 
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mg/ml. Five microlitres of each extract were impregnated into sterile Whatman 
filter paper d iscs (6 mm diameter) and dried under a strea m o f sterile air. 
Bacteria were streaked onto petri dishes with GC agar base medium by using 
sterile swabs a nd th e p late d ried for 5 min. The p rocedure was done i n 
triplicate. Ciprofloxacin and penicillin (1 µg /disc) were used as  a posi tive 
control. W ater and D MSO were used as negative and so lvent controls 
respectively. Discs were applied to  th e d ry surface o f a Petri dish with GC 
agar base medium and bacteria. The plates were inverted and incubated at 37 
°C in 5% CO2 for 24 h. The assay was repeated twice with two replicates per 
assay. 
 
The activity of plant extracts against N. gonorrhoeae was measured as 
indicated by clear zones of inhibition. Percentage of inhibition was calculated 
by comparing the distance of the sample to the distance of the positive control 
using the equation below: (by measuring the diameter of the inhibition zone 
including the disk). 
 
 
Gonococcal % inhibition= 
 
 
2.2.4. Antibacterial screening 
 
2.2.4.1. Preparation of microbial stock cultures 
 
Bacterial stock strains used for the antibacterial bioasssays were cultured in 
Mueller-Hinton (MH) agar (Merck, Germany). Sterile MH (25 ml) was poured 
into p lastic Petri dishes and a llowed to  gel. The p lates were allowed to  cool 
overnight at 4 °C after which stock strains of the bacteria were streaked and 
sub-cultured. The bacteria-inoculated plates were incubated at 37 °C for 24 h 
to allow bacterial colonies to develop. The plates were then stored at 4 °C to 
prevent further bacterial growth. The sto cks were sub-cultured f ollowing the 




2.2.4.2. Microdilution bioassay 
 
Minimum inhibitory concentration (MIC) values for antibacterial activity of the 
twelve medicinal plants were determined using the microdilution bioassay in a 
96-well (Greiner Bio-one GmbH, Germany) microplate (ELOFF, 1998). One 
hundred microlitres of each redissolved sample (50 mg/ml) in 80% ethanol 
were two-fold serially diluted with sterile distilled water, in duplicate down a 
96-well microplate for four bacteria strains. A similar two-fold serial dilution of 
neomycin (0.1 mg/ml, Sigma) was used as a positive control against each 
bacterium. Water, 80% EtOH and bacteria-free MH broth were included as 
negative controls. Overnight MH broth cultures (incubated at 37 °C in a water 
bath with shaking) of the four bacterial strains (B. subtilis ATCC 6051 and S. 
aureus ATCC 12600 E. coli ATCC 11775 and K. pneumoniae ATCC 13883) 
were diluted with sterile MH broth (1 ml bacteria/50 ml MH broth) to give final 
inoculums of approximately 106 cfu/ml (colony forming units). One hundred 
microlitres of each bacterial culture were added to each well. The plates were 
covered with parafilm and incubated overnight at 37 °C. Bacterial growth was 
tested by adding 50 µl of 0.2 mg/ml p-iodonitrotetrazolium chloride (INT) to 
each well and the plates incubated at 37 °C for 1 h. Bacterial growth in the 
wells was indicated by a red-pink colour, whereas clear wells indicated 
inhibition of growth by the test sample. MIC values were recorded as the 
lowest concentration of extract showing a clear well. Each assay was 
repeated twice with two replicates. 
 
2.2.5. Antifungal screening 
 
2.2.5.1. Preparation of microbial stock culture 
 
The fungal stock (C. albicans) used for the antifungal bioassays was cultured 
in Yeast Malt (YM) agar (Becton Dickinson, USA). Sterile YM (25 ml) was 
poured into plastic Petri dishes and allowed to gel following the procedure 




2.2.5.2. Microdilution bioassay 
 
The antifungal activity of the plant extracts was evaluated against C. albicans 
(ATCC 10231) using the micro-dilution assay (ELOFF, 1998) modified as an 
antifungal assay (MASOKO et al., 2007). An overnight fungal culture was 
prepared in 10 ml YM broth. Four hundred microliters of the overnight C. 
albicans culture were added to 4 ml sterile saline solution (0.85%). The 
absorbance was read at 530 nm and adjusted with either sterile saline or 
fungal culture solution to match that of a 0.5 M McFarland standard solution of 
0.25-0.28 absorbance units. From this prepared stock, a 1:1000 dilution with 
sterile YM broth was prepared to give an approximately 106 CFU/ml culture. 
 
One hundred microlitres of each plant extract were resuspended in 80% 
ethanol to a concentration of 50 mg/ml and two-fold serially diluted with sterile 
distilled water, in duplicate down a 96-well microtitre plate. A similar 2-fold 
serial dilution of Amphotericin B (Sigma-Aldrich) (2.5 mg/ml) was used as a 
positive control while 80% ethanol, water and fungal free broth were included 
as negative and/or solvent controls respectively. To each of the wells 
containing the test and control solutions, 100 µl of the dilute fungal culture 
was added and incubated for 24 h at 37 °C. To indicate fungal growth, 50 µl of 
0.2 mg/ml INT was added to each well, and the plates were incubated for a 
further 24 h. The wells which displayed no change in colour represented 
antifungal activity. The MIC was taken as the lowest concentration of plant 
extract to inhibit growth of the tested fungus after 48 h. After noting the MIC, 
50 µl YM broth was added to the clear wells to determine whether the 
inhibition was fungicidal. The microplates were re-covered with parafilm and 
incubated for a further 24 h after which the MFC (minimum fungicidal 
concentrations) values were noted. In the case where there was no growth of 
fungus in the last clear well even after addition of YM broth to clear wells, the 





2.3. Results and Discussion 
 
2.3.1. Antigonococcal activity 
 
The development of antibiotic resistance for pathogenic microorganisms is a 
major health concern worldwide, especially that of N. gonorrhoeae, which is 
also known to cause infertility amongst women (CHOMNAWANG et al., 
2009). The twelve medicinal plants were tested against N. gonorrhoeae using 
disc diffusion methods and the results are presented in Table 3. Three levels 
of activity were used: 0–44% not active; 45–70% moderate; 70–100% good 
activity. PE extracts of X. caffra leaves and roots, E. capensis leaves and B. 
speciosus stems, exhibited good activity against N. gonorrhoeae (> 70%). The 
DCM extracts of E. capensis leaves showed the best inhibition percentage 
(96%), O. lanceolata roots (82%) and X. caffra leaves (79%). The EtOH 
extracts of B. speciosus bark and O. lanceolata roots showed good inhibition 
percentage (72 and 87%). No inhibition was observed in water extracts, 
negative control and penicillin therefore results were not included in the table. 
Ciprofloxacin contain polar compound for that reason it diffuse thru agar more 
than penicillin this could be the reason ciprofloxacin showed best inhibition 
percentage than penicillin. It was not surprisingly to observe no activity in 
water extracts.  It has often been reported that water extracts have low/poor 
biological activity (LUSEBA et al., 2007; RABE and VAN STADEN, 1997). 
This could also due to the lack of synergitic effect; because traditionaly whole 
plant part or different plant parts are prepared as mixture in form of (decoction 
or infusion). Traditional plant extarcts are soaked for a remedy to be more 
active; therefore the activity could be from polar saponins in water extracts 
and longer term extraction. The treatment of venereal diseases by traditional 
healers could be through the stimulation of the immune system or direct 
inhibition of microorganism or the therapeutic effect could be influenced by 
spiritual beliefs. 
 
SHOKEEN et al. (2005, 2009) and CHOMNAWANG et al. (2009) showed the 
potency of medicinal plants against N. gonorrhoeae. A natural compound p-
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methoxybenzylisothiocyanate isolated from Lepidium bonariense have already 
































For the current study, these levels of activity were used: 0-44% not active; 45-70% moderate; 70-100% good activity.  
Values boldly-written are considered very active.  
 
 
Plant species Plant part  %inhibition %inhibition %inhibition 
  PE DCM EtOH 
Aloe chabaudii Root 65±0.0 50±1.3 46±1.0 
Adansonia digitata Bark 44±0.0 55±2.0 58±0.0 
Acacia karroo Bark 51±2.3 45±0.0 44±0.0 
Bolusanthus speciosus Leaf 44±0.0  65±0.0 53±1.2 
Bolusanthus speciosus Bark 65±4.3 54±1.3 72±1.3 
Bolusanthus speciosus Stem 75±2.3 59±1.3 52±1.3 
Elephantorrhiza burkei Root 51±2.3 51±0.0 44±0.0 
Ekebergia capensis Leaf 77±6.5 96±6.8 45±1.0 
Ekebergia capensis Bark 57±7.2 58±0.0 52±3.2 
Grewia occidentalis Root 53±2.3 45±0.0 50±2.7 
Osyris lanceolata Leaf 55±0.0 70±2.7 45±1.0 
Osyris lanceolata Root 44±0.0  82±4.7 87±11.0 
Peltophorum africanum Bark 56±2.3 45±1.0 44±0.0  
Pterocarpus angolensis Leaf 68±2.7 46±1.0 44±0.0  





Table 3: continuation 
Plant species Plant part  %inhibition %inhibition %inhibition 
  PE DCM EtOH 
Pterocarpus angolensis Bark 65±0.0 52±1.3 47±0.0 
Pappea  capensis Leaf 65±4.3 57±3.2 44±0.0  
Ximenia  caffra Leaf 73±4.3 79±3.2 44±0.0  
Ximenia caffra Root 87±4.3 44±0.0 56±1.0 
Ciprofloxacin +ve control 1µg/disk (13.8±0.0 ) 100±00  
 
For the current study, these levels of activity were used: 0-44% not active; 45-70% moderate; 70-100% good activity.  













Effective treatments are becoming increasingly limited because of the development 
of resistance or decreased susceptibility to the few antibiotics, which remain effective 
against N. gonorrhoeae, coupled with a significant lack of evidence that either new 
antimicrobial agents or combinations of older agents would be effective 
(WORKOWSKI et al., 2008; LIVERMORE, 2009).  
The cell wall of N. gonorrhoeae has many similarities to that of other Gram-negative 
bacteria. The only difference is that it has surface proteins such as Opa proteins 
(TAPSALL, 2001). The host is unable to develop an immunological memory against 
the N. gonorrhoeae resulting in the possibility for reinfection because Opa proteins 
bind to receptors on immune cells to prevent an immune response (TAPSALL, 
2001). Another important characteristic of N. gonorrhoeae is its antigenic variability. 
Through this process, N. gonorrhoeae has the ability to acquire genetic material from 
related organisms and to evade the hosts immune system (TAPSALL, 2001). These 
outer membranes affect permeability and penetration of antibiotics into the pathogen 
(TAPSALL, 2001).  
 
In recent years, resistance of N. gonorrhoeae to antibiotics has increased rapidly and 
reduced the options for treatment. Due to this, it is now rated as an emergence multi-
drug resistant pathogen (WHO, 2011). Increase in antibiotic resistance may be due 
to the impermeability of the outer membranes. These membranes may probably 
affect the inhibition of N. gonorrhoeae by water extracts. According to WHO (2011) 
unrestricted access to antimicrobials, inappropriate selection and overuse of 
antibiotics, and suboptimal quality of antibiotics, as well as genetic mutations within 
the organism have contributed to the development of resistance in N. gonorrhoeae 
including interaction and exchange of genetic material with other co-infections. 
 
DEGUCHI et al. (2010) suggested that a comprehensive global program is needed, 
including surveillance for antimicrobial resistance in N. gonorrhoeae in order to 
prevent the further emergence and international spread of drug resistance, and to 
allow the selection of appropriate treatments. The strategies for the control of 
gonorrhea have relied on the use of highly effective drugs (RAHMAN et al., 2001). 
The results obtained in this study indicate the existence of antimicrobial compounds 
in the crude extracts and the good activity observed from some of the plant extracts 
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tested in this study could lead to the isolation of effective antigonococcal compounds 
that can penetrate into N. gonorrhoeae surface proteins.  
 
2.3.2. Antibacterial activity 
 
The antibacterial MIC values of the extracts of the medicinal plant extracts tested in 
this study are presented in Table 4. FABRY et al. (1998) defined potentially useful 
activity for crude solvent extracts of plants to be considered as having good activity if 
they have MIC values <8 mg/ml, whilst GIBBONS (2005) suggests that isolated 
phytochemicals should have MIC <1mg/ml. However, in this study MIC values <0.1 
mg/ml were considered to be excellent antibacterial activity. The extracts showed a 
broad spectrum of activity against all bacterial strains. The DCM and EtOH extracts 
of B. speciosus bark and stem extracts showed the best antibacterial activity against 
B. subtilis and S. aureus. Aloe chabaudii, A. digitata and G. occidentalis exhibited the 
least antibacterial activity against all the strains.  
 
According to RABE and VAN STADEN (1997), Gram-negative bacteria are more 
resistant than Gram-positive ones. Gram-negative bacteria have an outer membrane 
acting as a barrier to environmental substances including antibiotics (PALOMBO and 
SEMPLE, 2001). The observed activity of some B. speciosus bark DCM and EtOH 
extracts against Gram-negative bacteria, which are often resistant to antimicrobial 
agents, could be explained by the fact that the active compounds may act by 
inhibiting the bacterial growth without necessarily penetrating into the bacterial cell 
itself. It has often been reported that water extracts have low/poor biological activity 
(LUSEBA et al., 2007; RABE and VAN STADEN, 1997). However, in this study 
water extracts of X. caffra leaf exhibited good antibacterial activity with an MIC value 
of 0.049 mg/ml against S. aureus. This justifies the use of water extracts of this plant 
in traditional medicine (MULAUDZI et al., 2009). The activity observed from B. 
speciosus could be due to the isolated active compounds such as medicarpan, 
genistein, 6,6′-dihydroxy-4′-methoxy-2-arylbenzofuran (bolusanthin IV) and 
flavonoids, which were previously shown to have antibacterial activity against B. 




Table 4: Antibacterial minimal inhibitory concentrations (MIC mg/ml) of 12 medicinal plants used by the Venda people of South 
Africa 
Plant species Plant part                                                             MIC (mg/ml) 
  
  PE DCM EtOH Water 
B.s. E.c. K.p. S.a. B.s. E.c. K.p. S.a. B.s. E.c. K.p. S.a. B.s. E.c. K.p. S.a. 
Aloe chabaudii Root 6.25 3.125 1.56 1.56 1.56 1.56 3.125 1.56 3.125 3.125 3.125 3.125 >12.5 6.25 6.25 3.125 
Adansonia  digitata Bark 3.125 3.125 6.25 12.5 3.125 1.56 3.125 3.125 0.78 3.125 3.125 1.56 >12.5 3.125 3.125 3.125 
Acacia  karroo Bark 3.125 1.56 1.56 1.56 0.78 0.39 0.39 0.195 0.195 1.56 0.78 0.195 0.39 1.56 3.125 0.195 
Bolusanthus speciosus  Leaf 0.78 3.125 0.39 1.56 0.39 6.25 0.39 3.125 0.195 1.56 3.125 0.78 >12.5 0.78 1.56 3.125 
Bolusanthus speciosus  Bark 0.39 0.195 3.125 0.78 0.39 0.098* 0.195 0.098 0.025 0.098 0.195 0.098 3.125 3.125 0.78 1.56 
Bolusanthus speciosus  Stem 0.39 0.195 0.78 0.78 0.012 0.78 0.195 0.025 0.098 1.56 0.78 0.098 >12.5 12.5 3.125 6.25 
Elephantorrhiza  burkei Root 6.25 3.125 3.125 12.5 3.125 1.56 3.125 6.25 0.39 0.39 0.78 0.025 0.39 1.56 1.56 0.39 
Ekebergia capensis Leaf 0.39 0.78 1.56 3.125 0.78 0.78 0.78 0.78 1.56 3.125 1.56 0.78 6.25 6.25 3.125 6.25 
Ekebergia capensis  Bark 0.78 1.56 1.56 3.125 0.78 1.56 1.56 1.56 0.098 3.125 1.56 0.78 1.56 3.125 1.56 0.78 
Grewia occidentalis Root 3.125 3.125 3.125 12.5 3.125 3.125 1.56 3.125 3.125 3.125 3.125 0.78 >12.5 6.25 6.25 12.5 
Osyris lanceolata  Leaf 6.25 1.56 1.56 6.25 0.39 0.78 0.78 6.25 0.78 3.125 1.56 0.39 1.56 3.125 1.56 0.78 
Osyris lanceolata Root 0.098 3.125 1.56 0.195 0.098 3.125 1.56 0.195 0.098 3.125 0.195 0.78 6.25 6.25 6.25 0.78 
Peltophorum africanum Bark 1.56 0.78 0.78 3.125 1.56 0.78 1.56 3.125 0.195 0.39 0.195 0.098* 0.39 1.56 0.78 0.78 
 
B.s.= Bacillus subtilis; E.c.= Escherichia coli; K.p.= Klebsiella pneumoniae; S.a.= Staphylococcus aureus *Values boldly-written are considered 
very active (< 0.1 mg/ml).  The MIC values (μg/ml) for Neomycin (positive control) were: B. subtilis = 1.531 ×10-3; E. coli = 3.063×10-3; S. aureus 





Table 4: continuation 
Plant species Plant part                                                       MIC (mg/ml) 
  
  PE DCM EtOH Water 
B.s. E.c. K.p. S.a. B.s. E.c. K.p. S.a. B.s. E.c. K.p. S.a. B.s. E.c. K.p. S.a. 
Pterocarpus angolensis Leaf 3.125 1.56 3.125 0.78 1.56 1.56 0.78 3.125 0.39 1.56 0.78 0.78 >12.5 1.56 0.78 0.78 
Pterocarpus angolensis Bark 3.125 3.125 1.56 6.25 0.78 0.39 0.195 3.125 0.012 0.78 1.56 0.195 0.39 3.125 3.125 3.125 
Pappea capensis Leaf 0.78 0.39 0.78 0.39 0.78 0.78 1.56 1.56 0.195 0.78 0.78 0.098 >12.5 3.125 3.125 3.125 
Ximenia caffra  Leaf 1.56 3.125 3.125 6.25 0.78 3.125 3.125 6.25 0.39 0.195 0.195 0.025 0.39 0.39 0.78 0.049 
Ximenia caffra Root 0.39 1.56 1.56 0.78 0.39 1.56 1.56 0.78 0.195 1.56 0.78 0.195 0.39 3.125 6.25 3.125 
 
B.s.= Bacillus subtilis; E.c.= Escherichia coli; K.p.= Klebsiella pneumoniae; S.a.= Staphylococcus aureus *Values boldly-written are considered 
very active (< 0.1 mg/ml).  The MIC values (μg/ml) for Neomycin (positive control) were: B. subtilis = 1.531 ×10-3; E. coli = 3.063×10-3; S. aureus 




Ximenia caffra extracts showed good antibacterial activity against S. aureus, E. coli 
and P. aeruginosa (OKEMO et al., 2004). Ximenia caffra contains simple phenolic 
compounds such as coumaric, vanillic and ferulic acids which have often been 
implicated in antibacterial activity (NDHLALA et al., 2008b). The activity observed 
from O. lanceolata could be due to the isolated compound octandronic acid, and 20-
epikoetjapic acid which previously showed good antibacterial activity against B. 
subtilis, S. aureus, E. coli and P. aeruginosa (YEBOAH et al., 2010). The observed 
activity justifies further investigation to characterize the active constituents in the 
extracts of B. speciosus bark and stem, O. lanceolata roots, P. africanum bark, P. 
angolensis bark and X. caffra leaves.  
 
2.3.3. Antifungal activity 
 
Candida albicans is one of the fungi that play a role in venereal disease, especially in 
immunocompromised and HIV/AIDS patients. The plant extracts tested showed a 
broad spectrum of antifungal activity against C. albicans (Table 5). The results 
indicate MIC and minimum fungicidal concentration (MFC) values ranging from 0.012 
to 12.5 mg/ml. It is important to determine whether the active extracts are fungistatic 
(able to slow or retard the multiplication of fungi) or fungicidal (able to destroy fungi). 
The results of this study took both of these aspects into consideration.  
 
The DCM extracts of B. speciosus bark showed the highest activity with MIC and 
MFC value of 0.012 mg/ml respectively. This shows that B. speciosus is fungicidal to 
C. albicans at this concentration. The 80% EtOH extracts of B. speciosus leaf, bark, 
O. lanceolata root, P. angolensis leaf, P. capensis leaf, E, capensis leaf and X. caffra 
leaf showed good antifungal activity against C. albicans. The activity observed from 
O. lanceolata could be due to compounds such as 1α, 9 β-Difuranoyloxy-2-oxo-
dihydro- β –agarofuran, 1α, 9β-Difuranoyloxy-2-oxo-3-enedihydro-β agarofuran, 1α, 
9β Difuranoyloxydihydro-β–agarofuran, octandronic acid, and 20-epikoetjapic acid all 
of which have previously displayed antifungal activity against C. albicans (YEBOAH 
et al., 2010). As in the antibacterial assay, A. chabaudii roots and A. digitata bark 




According to POLAK (1999) a truly safe, fungicidal drug does not yet exist. However, 
the observed results from B. speciosus bark suggested a potential lead to the 
isolation of a fungicidal drug. The good antifungal activity can be the lead to 





Table 5: Antifungal activity (MIC and MFC) of 12 medicinal plants used by the Venda people 
Plant species Plant part         MIC (mg/ml)            MFC (mg/ml) 
  PE DCM EtOH Water PE DCM EtOH Water 
Aloe chabaudii Root 6.25 6.25 3.125 12.5 6.25 6.25 3.125 >12.5 
Adansonia digitata Bark 3.125 12.5 6.25 6.25 3.125 12.5 6.25 12.5 
Acacia karroo Bark 6.25 6.25 3.125 6.25 12.5 6.25 3.125 >12.5 
Bolusanthus speciosus Leaf 3.125 0.39* 0.195 6.25 3.125 1.56 0.78 6.25 
Bolusanthus speciosus Bark 6.25 0.012 0.195 6.25 12.5 0.012 0.78 12.5 
Bolusanthus speciosus Stem 6.25 0.195 1.56 6.25 6.25 3.125 3.125 6.25 
Elephantorrhiza burkei Root 6.25 6.25 1.56 3.125 6.25 6.25 3.125 6.25 
Ekebergia capensis Leaf 6.25 3.125 0.39 6.25 12.5 6.25 3.125 12.5 
Ekebergia capensis Bark 3.125 3.125 6.25 6.25 3.125 6.25 6.25 12.5 
Grewia  occidentalis Root 6.25 6.25 6.25 12.5 6.25 12.5 6.25 12.5 
Osyris lanceolata Leaf 3.125 1.56 6.25 6.25 3.125 1.56 6.25 6.25 
Osyris lanceolata Root 3.125 3.125 0.098 6.25 3.125 3.125 6.25 6.25 
Peltophorum africanum Bark 6.25 3.125 3.125 1.56 6.25 3.125 3.125 12.5 
Pterocarpus angolensis Leaf 3.125 3.125 0.195 6.25 3.125 3.125 1.56 12.5 
 
The MIC and MFC of Amphotericin B (µg/ml) (positive control) were 9.77 × 10-3 and 7.81 × 10-2 respectively 







Table 5: continuation 
Plant species Plant part MIC (mg/ml) MFC (mg/ml) 
  PE DCM EtOH Water PE DCM EtOH Water 
Pterocarpus angolensis Bark 3.125 3.125 6.25 3.125 3.125 3.125 6.25 12.5 
Pappea capensis Leaf 6.25 1.56 0.195 3.125 12.5 1.56 3.125 3.125 
Ximenia caffra Leaf 1.56 1.56 0.78 0.78 1.56 1.56 1.56 1.56 
Ximenia caffra Root 3.125 3.125 3.125 1.56 6.25 3.125 3.125 12.5 
 
The MIC and MFC of Amphotericin B (µg/ml) (positive control) were 9.77 × 10-3 and 7.81 × 10-2 respectively 






The plants used for conditions related to venereal diseases by the Venda people 
were successfully evaluated in order to justify their uses in traditional medicine as 
well as in the quest for the search for natural products that can resolve the issue of 
drug resistance. The broad spectrum antimicrobial activity of some plants justifies 
the use of these medicinal plants in traditional medicine. Bolusanthus speciosus and 
X. caffra exhibited the best antigonococcal, antifungal and antibacterial activities. 
Adansonia digitata and A. chabaudii exhibited poor activities in all the assays. 
Traditionally water, not organic solvents, are used to make decoctions. However, in 
this case it was surprising because no activity was observed in water extracts 
against N. gonorrhea. Maybe these plants exhibited the activity when they are in 
synergism.  
 
They are many co-infections involved when a patient is infected with one pathogen 
for example with venereal infections S. aureus, causes skin diseases (BUWA and 
VAN STADEN, 2006), while E. coli and K. pneumoniae infects the urinary tract 
(SLEIGH and TIMBURY, 1998) Untreated venereal infections can lead to other 
diseases such as conjunctivitis which can be caused by B. subtilis (BUWA and VAN 
STADEN, 2006). It was interesting to note the activity of some of the plants against 
bacteria that are known to cause co-infection with venereal infections. The same 
plants exhibited good activity against N. gonorrhea. This observation shows that 
these plants are used purposely for treating all infections related to gonorrhea. 
Bolusanthus speciosus and X. caffra can be the best plants to use to prevent 
gonococcal reinfection and antigenic variability.  
 
Modern drugs are based on the lock and key theory, which uses only one target to 
treat a single disease. However, this theory usually fails because many diseases 
involve multiple factors (KONG et al., 2009). Therefore antimicrobial activity of B. 
speciosus and X. caffra clearly shows that medicinal plants can be the key to dispel 
this theory. The results obtained in this study only offer supporting evidence for 
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effective use of these extracts. More in vitro confirmatory tests using other assays 
and/or in vivo tests are still required.  
 
Publication from this chapter: R.B. Mulaudzi, A.R. Ndhlala, M.G. Kulkarni, J.F. 
Finnie, J. Van Staden 2011. Antimicrobial properties and phenolic contents of 
medicinal plants used by the Venda people for conditions related to venereal 





























CHAPTER 3: Anti-inflammatory and Anti-HIV-1 Screening 
 
3.1. Introduction  
 
Enzyme catalysis is involved in several physiological, biochemical and disease 
processes essential for life, thus making enzymes attractive in drug discovery. This 
is due to the fact that enzymes are able to be inhibited by small molecular weight 
compounds. In light of this characteristic enzymes are now the targets of new drug 
discovery in pharmaceutical and biotechnological research (COPELAND, 2005).  
 
3.1.1. Inflammatory process 
 
Inflammation is the response of living tissues to injury such as physical trauma, 
chemical irritations, ultraviolet radiation and burns, as well as microbial pathogen 
infections (IWALEWA et al., 2007; PAN et al., 2010). It involves the mobilization of 
inflammatory responses that serve as physiological barriers against the spread of 
infection, eliminating foreign pathogens and repairing injured tissues as well as the 
clearance of the stimuli (COHN and LANGMAN, 1996; PAN et al., 2010). Redness, 
heat, pain, swelling and loss of function are the basic signs of inflammation in the 
body (MOLVI et al., 2007). Inflammation is rapid and self-limiting, but abnormal 
resolution and prolonged inflammation causes various chronic disorders classified as 
acute or chronic inflammatory diseases (CALDER et al., 2009). Acute inflammation 
is characterized by slow exudation of fluid, plasma proteins and the emigration of 
leukocytes, predominantly neutrophils. Chronic inflammation delays the immune 
response and is of prolonged duration, a week or month (MOLVI et al., 2007). 
Chronic inflammatory responses lead to a pathological progression of chronic 
illnesses (such as cancer, neurological disease, metabolic disorder, chronic lung 
disease and cardiovascular diseases) that are characterized by infiltration of 
inflammatory cells, excess production of cytokines, deregulation of cellular signalling 
and loss of barrier function (PAN et al., 2010). According to PAN et al. (2010) 
reduction/eliminating of chronic inflammation is a beneficial strategy to fight several 




Inflammation responses are triggered by the biosynthesis of a group of compounds 
known as prostaglandins from arachidonic acid (VANE and BOTTING, 1997; 
SALMON and HIGGS, 1994). Prostaglandins are involved in many physiological 
processes, where they play an important role in the maintenance of mucosal integrity 
in the stomach, homeostasis and regulation of renal function (KURUMBAIL et al., 
2001; MORITA, 2002; PATRIGNANI et al., 2005). The enzymes that convert 
arachidonic acid to prostaglandins are referred to as cyclooxygenases (COX) 
(MORITA, 2002). COX exists in two isoforms commonly referred to as COX-1 and 
COX-2. These two isoforms are upregulated in a variety of circumstances (WANG 
and DUBOIS, 2011). COX-1 is known to be involved in normal physiological 
functions. Recently COX-1 has been shown to be upregulated in various carcinomas 
and to have a central role in tumorigenesis. COX-2 is involved in rheumatic 
diseases, inflammation and tumorigenesis (JABBOUR and SALES, 2004).  
 
3.1.2. Anti-Inflammatory agents 
 
The nonsteriodal anti-inflammatory drugs (NSAIDs) exert their relieving properties, 
analgesic, and antipyretic effects mainly by inhibiting COX enzymes (PATRIGNANI 
et al., 2005). Aspirin, ibuprofen, piroxicam, indomethacin, and sulindac are well 
known examples of NSAIDs that are commonly used for treating arthritis, 
rheumatisms, pain and fever (COPELAND, 2005; MOLVI et al., 2007). Their 
mechanism of action includes inhibition of both the COX-1 and COX-2 isoenzymes 
(PATRIGNANI et al., 2005). Inhibition of COX-2 is thought to mediate the 
therapeutic actions of NSAIDs, while the inhibition of COX-1 results in unwanted 
side-effects, mostly in the gastrointestinal tract, by causing ulceration, bleeding, 
perforation, and obstruction (FITZGERALD and PATRONO, 2001; PATRONO et 
al., 2001). There is growing interest in the search for anti-inflammatory and analgesic 
drugs with no side effects. A number of compounds derived from medicinal plants 
are already considered as effective and safer for the treatment of various diseases, 





3.1.3. Human immunodeficiency virus infections 
 
Human immunodeficiency virus (HIV) is a lentivirus that causes acquired 
immunodeficiency syndrome (AIDS) and is considered pandemic (WEISS, 1993). 
The infection is a condition that causes a progressive failure of the immune system 
and allows life-threatening opportunistic infections and cancer to thrive in humans. It 
has become one of the world‘s most serious health and development challenges 
since 1981 (WHO, 2003). This infection is primarily spread from person to person 
mainly through sexual contact. The genital tract acts as a point of entry and reservoir 
in both sexes (VAN VUUREN and NAIDOO, 2010).   
 
The complex process of HIV infection begins when the HIV uses cells of the immune 
system (macrophages and helper T cells) as sites for reproduction resulting in the  
production of multiple copies of the viral genetic material (RNA), which are packaged 
to infect new viral hosts (THAKUR et al., 2010). The infection produces a complex 
multifactorial condition, associated with immunodeficiency and autoimmune 
inflammation. It also produces gradual effects on the body‘s defence mechanisms 
thereby leading to such opportunistic infections as tuberculosis, pneumonia, 
intestinal tract infections, as well as debilitating weight loss, diarrhoea, neurologic 
conditions, and cancers such as Kaposi‘s sarcoma and certain types of lymphomas 
(VERMANI and GARG, 2002; THAKUR et al., 2010). These infections cause the 
immune system to remain in a state of chronic activation resulting in decreased 
immune surveillance and susceptibility to opportunistic infections, growth of 
neoplasm and ultimate progression to the full development of the AIDS syndrome 
(YOUNG, 2003).  
 
3.1.4. HIV prevalence 
 
Currently there are approximately 33.4 million people living with HIV/AIDS worldwide 
(UNAIDS/WHO, 2008a). Reports from all regions of the world reveal that, almost all 
those living with HIV (96%) reside in low- and middle-income countries, particularly 
in sub-Saharan Africa (UNAIDS/WHO, 2008b). The nine countries with the highest 
HIV prevalence worldwide are all located in this sub-region, with each of these 
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countries experiencing adult HIV prevalence greater than 10% (UNAIDS, 2009). 
However, the epidemic appears to have stabilized in most regions, although 
prevalence continues to increase in Eastern Europe and central Asia, due to a high 
rate of new HIV infections (UNAIDS, 2010). Sub-Saharan Africa remains the most 
heavily affected region, with 22.5 million adults and children living with HIV/AIDS 
(UNAIDS, 2010). 
 
South Africa is home to the world‘s largest population of people living with HIV (5.7 
million) (UNAIDS/WHO, 2008a). UNAIDS (2010), estimate that 310,000 South 
Africans died of AIDS in 2009. Almost one-in-three women aged 25-29, and over a 
quarter of men aged 30-34, are living with HIV (HUMAN SCIENCES RESEARCH 
COUNCIL, 2009). The high HIV prevalence in developing countries may be due to 
the high cost and limited availability of antiretroviral drugs. 
 
3.1.5. Anti- HIV agents 
 
Human immunodeficiency virus type 1(HIV-1) reverse transcriptase (RT) is capable 
of catalyzing reverse transcription of HIV-RNA into a double stranded DNA via 
polymerase and RNase H activities. Reverse transcriptase is an important enzyme in 
the HIV replication cycle. Inhibition of RT is one of the most important targets in 
disrupting the replication of HIV and has been one of the primary therapeutic 
strategies in HIV/AIDs patient treatment (LAI et al., 2009; HUANG et al., 2011). The 
role of RT mechanism has guided the development of several inhibitors which are 
now widely used in current HIV/AIDS therapy (CASTRO et al., 2006). Standard HIV 
therapies available for the treatment of HIV-1 infections include nucleoside RT, non-
nucleoside RT and protease inhibitors (MENÉNDEZ-ARIAS, 2008).   
These inhibitors have different roles in the inhibition processes. Nucleoside RT 
inhibitors such as zidovudine (AZT) and lamivudine (3TC), bind directly to the active 
site of RT polymerase and terminate DNA synthesis after incorporation onto the 
newly synthesized DNA, while non-nucleoside RT inhibitors (efavirenz and 
nevirapine) bind to an allosteric site on RT (LAI et al., 2009). Protease inhibitors 
such as nelfinavir and saquinavir block or inactivate endogenous proteolytic and 
phospholytic enzymes (MENÉNDEZ-ARIAS, 2008). All these treatments contribute 
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in reducing progression of HIV. However, there are disadvantages related to these 
drugs, such as side effects that limit the use of these antiviral drugs (i.e. AZT) and 
some of them do not penetrate at an efficient inhibitory level, mostly protease 
inhibitors (MENÉNDEZ-ARIAS, 2008; DA SILVA et al., 2009). In addition, the 
emergence of drug-resistance, due to high mutation rates of HIV together with its 
rapid turnover in an infected individual, eventually can lead to antiretroviral failure 
(MENÉNDEZ-ARIAS, 2008; DA SILVA et al., 2009). Although these therapies help 
in improving the life quality of HIV patients and slow down the progression of AIDS, 
the condition still remains a major health problem in the world today (DA SILVA et 
al., 2009). Therefore there is need to develop of new RT inhibitors that can inhibit 
clinically prevalent resistant viruses. 
Inflammation is a major risk factor for various human diseases including venereal 
diseases. Screening of some medicinal plants for anti-inflammatory agents have 
been reported by McGAW et al. (1997) and TAYLOR and VAN STADEN (2001).  
Many medicinal plants have been shown to be potentially useful as agents against 
many diseases including inhibition of the HIV-1 reverse transcriptase enzyme. 
Screening of some medicinal plants for anti-HIV agent have been reported by 
BESSONG et al. (2005), KLOS et al. (2009) and TSHIKALANGE et al. (2008).  
In this study twelve medicinal plants were evaluated for the possible inhibition of 














3.2. Materials and Methods 
 
3.2.1. Plant collection and sample preparation 
 
Plants were collected and prepared as described in Section 2.3.1. of Chapter 2. 
Except that for HIV-1 reverse transcriptase organic solvent used was 50% methanol 
 
3.2.2. Preparation of plant extracts 
The extracts were resuspended to a concentration of 10 mg/ml for cyclooxygenase. 
For the HIV-1 reverse transcriptase (RT) inhibitory bioassay, organic extracts were 
resuspended in 50% methanol to a concentration of 20 mg/ml. 
 
3.2.3. Enzyme and substrate preparation for the Cyclooxygenase 
(COX-1 and COX-2) assays 
 
The COX-1 enzyme isolated from ram seminal vesicles and the human recombinant 
COX-2 containing a six histidine sequence near the N-terminus isolated from a 
Baculovirus over expression system in Sƒ 21 cells were obtained from Sigma Aldrich 
(USA).  
The enzymes were diluted with Tri (hydromethyl) aminomethane (TRIS) storage 
buffer (pH 8.0) to obtain 50 µl aliquots, each with 75 units of enzyme concentration 
per aliquot. The prepared COX enzymes were stored in an ultra-freezer at -70 °C. 
 
3.2.4. COX-1 inhibitory bioassay 
 
The COX-1 bioassay was performed as described by JÄGER et al. (1996). The 
enzyme was activated with 1250 μl of co-factor solution (3 mg/ml L-epinephrine and 
3 mg/ml reduced glutathione in 0.1 M Tris buffer, at pH 8.0) and pre-incubated on ice 
for 5 min, 60 μl of the enzyme solutions were added to each sample solution (2.5 µl 
plant extract and 17.5 µl water) in duplicate and the mixture was incubated at room 
temperature for 5 min in 1.5 ml Eppendorf tubes. The extracts were tested at a 
concentration of 10 mg/ml (organic solvent were resuspended in 80% ethanol and 
aqueous extract in water) giving a final concentration of 250 µg/ml per test solution. 
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Two se parate se ts of Eppendorf t ubes, background (the  e nzyme w as ina ctivated 
with HCl before incubation), solvent blank (containing water instead of sample) and 
positive control (containing 5 μM indomethacin obtained from Sigma) were included 
in the t est. The rea ction w as initiated by adding 20 μl 14C-arachidonic a cid (16 
Ci/mol, 30 μM) to each Eppendorf tube after 5 min of incubation. The mixtures were 
the incubated in a water bath at 37 ºC for 10 min and afterwards the reaction was 
stopped by adding 10 μl 2N HCl except in the background tubes. Columns w ere 
packed with sil ica gel (silica gel 60, 0.063-0.200 mm, Merck) to a hei ght of 3 cm i n 
Pasteur pipettes. Fou r m icrolitres (0.2 mg/ml) o f unlabeled p rostaglandins (PGE2: 
PGF2α 1:1) (Sigma-Aldrich) were added t o each  Eppendorf t ube as a c arrier 
solution. The te st solutions w ere applied t o th e co lumns w ith 1  m l of e luent 1 
[hexane: 1,  4 -dioxane: g lacial acetic acid ( 70:30:0.2 v: v : v)]. The application o f 
eluent 1 w as done i n order to se parate t he pr ostaglandins and unm etabolized 
arachidonic acid. A rachidonic acid was e luted first with 4  m l e luent 1. The 
prostaglandin p roducts w ere eluted w ith 3  ml of e luent 2 [ ethyl acetate: methanol 
(85:15 v: v)] and collected in scintillation vials. To each vial, 4 ml of scintillation fluid 
were added and the disintegration per minute (DPM) of the radioactive material was 
counted using a scintillation counter (Beckman LS 6000LL scintillation counter). The 
assay was repeated twice. Inhibition percentage was calculated using the equation 
below:  
 





where DPMextract is the disintegrations per minute for the plant extract, DPMbackground 
is the disintegrations per minute in which the enzyme was inactivated and DPMblank is 
the disintegrations per minute for the reaction mixture containing water. Results are 
presented as graphs ( means ± standard e rrors) of t wo i ndependent experiments. 







3.2.5. COX-2 inhibitory bioassay 
 
The COX-2 activity was assessed using a method described by NOREEN et al. 
(1998), with slight modifications (ZSCHOCKE and VAN STADEN, 2000). The 
procedure of the assay was the same as described in COX-1 Section 3.3.4 except 
that 6 mg/ml L-epinephrine was used instead of 3 mg/ml L-epinephrine in the 
preparation of the cofactor solution and 200 μM indomethacin instead of 5 μM. 
 
3.2.6. HIV-1 reverse transcriptase (RT) inhibitory bioassay 
 
The effect of the 12 medicinal plants against RT was evaluated using a non-
radioactive HIV-1 RT colorimetric ELISA kit obtained from Roche Diagnostics 
(Germany). The protocol supplied together with the kit was followed, under nuclease-
free conditions. The reverse transcriptase colourimetric assay takes advantage of 
the ability of RT to synthesize DNA, starting from the template/primer hybrid poly (A) 
× oligo (dT)15, by avoiding the use of [3H]- or [32P]-labeled nucleotides which are 
used in other classical RT assays. In place of radio-labeled nucleotides, digoxigenin- 
and biotin-labeled nucleotides in an optimized ratio are incorporated into one and the 
same DNA molecule, which is freshly synthesized by the RT. The detection and 
quantification of synthesized DNA as a parameter for RT activity is followed in a 
sandwich ELISA protocol. Biotin-labeled DNA binds to the surface of microtitre plate 
modules (MPM) with wells that were precoated with streptavidin. In the next step, an 
antibody to digoxigenin, conjugated to peroxidase (anti-DIG-POD), binds to the 
digoxigenin-labelled DNA. In the final step, the peroxidase substrate ABTS (2, 2'-
Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]- diammonium salt) is added. The 
peroxidase enzyme catalyzes the cleavage of the substrate, producing a coloured 
reaction product which is measured spectrophotometrically. 
 
The following solutions, provided with the kit were prepared according to the 
manufacturer instructions; Solution 1, HIV-1 reverse transcriptase (final 
concentration 2 ng/μl, corresponding to 10 mU/μl) stored at -70 ºC. Solution 2, 
incubation buffer. Solution 3, reaction mixture containing poly (A) x oligo (dT)15 (46 
mM Tris-HCl, 266 mM potassium chloride, 27.5 mM magnesium chloride, 9.2mM 
54 
 
DDT, 10 μM dUTP/dTTP, template/primer hybrid, 750 mA260 nm/ml). Solution 4, lysis 
buffer. Solution 5, anti-digoxigenin-peroxidase (anti-DIG-POD) (200 mU/ml). Solution 
6, washing b uffer and so lution 7 , A BTS substrate so lution and m icrotitre plate 
modules (MPM) precoated with streptavidin and postcoated with blocking reagent. 
 
Twenty m icro-litres of the resuspended p lant extracts (w ith final assay 
concentrations of 0.125, 0.25, 0.5, 1μg/ml) were mixed with 20 μl of recombinant 
HIV-1-RT (4 ng in lysis buffer) and 20 μl reaction mixture (solution 3) in sterile 
Eppendorf tubes and t he t ubes were incubated for 1 h at  37 °C. A fter a 1 h 
incubation period, the mixtures (60 μl) were transferred into MPM wells and covered 
with foil and incubated for 1 h at 37 °C after which the mixtures were removed from 
the MPM wells completely. The wells were rinsed five times with 250 μl of washing 
buffer (solution 6) per well for 30 s, the washing buffer being removed carefully after 
each wash. After washing, 200 μl of anti-DIG-POD (solu tion 5) was added to each 
well and the MPM were recovered with foil and incubated for 1 h at 37 °C. After the 
incubation p eriod, the so lution w as rem oved co mpletely f rom th e M PM wells a nd 
rinsed five times with 250 μl of washing buffer (solution 6) per  well for 30 s. After 
washing, 200 μl of ABTS substrate solution (solution 7) was added to each well and 
the MPM were incubated at room temperature for 5 min (a green colour appeared in 
the wells).  
 
The a bsorbance o f the rea ction mixture was th en measured at 405 n m using a  
microplate reader (Opsys MRTM, Dynex Technologies Inc.). Percentage of inhibition 
was calculated by comparing the absorbance of the sample to the negative control 
using the equation below: 
 
 




Where A bs405 nm  sample is the a bsorbance o f the rea ction w ith p lant e xtracts o r 
positive control at 405 nm and Abs405 n m negative control is the absorbance o f the 
reaction with water instead of sample at 405 nm. 
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The negative control consisted of water instead of sample. A reference control 
consisted of lysis buffer and no HIV-1 RT. Combivir® (GlaxoSmithKline) [lamivudine 
(1.0 mg/ml) + zidovudine (2.0 mg/ml)] and Kaletra® (Abbott) [lopinavir (8.9 mg/ml) + 
ritonavir (2.2 mg/ml)] were used as positive controls. Results were presented as 
means ± standard errors of two independent experiments; each experiment was 
done in duplicate. The IC50 values were calculated using GraphPad Prism version 
4.00 statistical software programs for Windows (GraphPad Software Inc.). 
 
3.3. Results and discussion 
 
3.3.1. COX-1 and COX-2 inhibitory activity 
 
The results of the percentage inhibition of COX-1 and COX-2 enzyme by the 12 
medicinal plants used for venereal and related diseases are presented in Figure 1. 
Four levels of activity were defined for the enzyme inhibition assays; with activity 
below 20% being considered insignificant, 20–40% low, 40–70% moderate and 70–
100% high (TAYLOR and VAN STADEN, 2001).  
 
All solvent extracts tested showed good inhibition activity towards COX-1 (moderate 
to high activity), except water extracts of A. digitata bark, O. lanceolata leaves and P. 
angolensis leaves and PE extracts of X. caffra leaves. However, water extracts of A. 
karroo bark, E. burkei roots, E. capensis leaves, P. africanum bark, P. angolensis 
bark, P. capensis leaves, X. caffra (leaves, roots) showed high activity (71.9 to 
100%). DCM, PE, EtOH extracts of A. chabaudii roots, A. digitata bark, A. karroo 
bark, B. speciosus leaves, B. speciosus bark, E. burkei roots, O. lanceolata roots, P. 
angolensis bark, P. capensis leaf,  and X. caffra roots showed high inhibitory activity 
towards COX-1 (>70%).  
Among the different solvent extracts tested, DCM extracts of most of the plant 
species displayed good activity towards COX-2 (moderate to high activity), with E. 
capensis bark, O. lanceolata leaves and roots, X. caffra leaves and roots being the 
only exception showing insignificant to low percentage inhibition. PE extracts of A. 
digitata bark, B. speciosus bark, G. occidentalis roots, P. africanum bark, P. 
56 
 
angolensis, leaves and roots and P. capensis leaf showed high inhibitory activity 
towards COX-2 (> 70%). No activity was recorded in the PE extracts of E. capensis 
leaves against COX-2. EtOH extracts of B. speciosus stems displayed high inhibitory 
activity (95.7%) towards COX-2. No activity was observed in the water extracts of E. 
capensis leaves, G. occidentalis roots, P. angolensis leaves and root and P. 
capensis leaves, the rest of the water extracts displayed insignificant to moderate 
inhibition.  
 
It has often been reported that activity in water extracts is not detected or yield false 
positives (LUSEBA et al., 2007). However, in this study, water extracts showed 
good activity toward COX-1, with the highest activity (100%) of A. karroo bark. Some 
phenolic compounds such as proanthocyanidins have antioxidant effects and have 
been used to treat inflammatory diseases (NDHLALA et al., 2008a). It has been 
reported that A. karroo bark is very rich in proanthocyanidin and flavonols (MALAN 
and SWARTZ, 1995). Flavonoids are known for their significant scavenging 
properties on oxygen radicals in vivo and in vitro, affecting various steps in the 
arachidonate cascade via cyclooxygenase or lipoxygenase (ABAD et al., 1995). A 
species containing a known anti-inflammatory compound has the potential to inhibit 
inflammatory processes (JÄGER et al., 1996). The mechanism of anti-inflammatory 
activities of A. karroo bark may be due to the presence of the above mentioned 
phytochemicals.  
 
Insignificant activity toward COX-2 could be due to the present of low lipophilic 
compounds in water extracts. TUNÓN et al. (1995) reported that lipophilic 
compounds are less likely to be found in water extracts, even if they are found they 
are in small quantities. PE and DCM extracts of A. digitata bark extracts showed 
good activity toward both COX-1 and COX-2, with insignificant activity in EtOH 
extracts toward COX-2 enzyme. These activities could be from proanthocyanidins, 
terpenoids, flavonoids and sterols that have been isolated from A. digitata (SHAHAT, 
2006). DCM and PE extracts of P. angolensis bark extracts showed good activity in 
both COX-1 and COX-2. The activity from P. angolensis could have resulted from 
isolated compounds epicatechin [(-)-epicatechin, epicatechin-3-O-galate, epicatechin 
(4beta-8)-epicatechin (B2), and a hexamer of epicatechin] (SAMIE et al., 2009). 
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Flavonoids are known to act through a variety of mechanisms to prevent and/or 
reduce inflammatory responses and they are likely to have a potential role in 
preventive and therapeutic roles in chronic inflammatory conditions (PAN et al. 
2010).  
 
Generally extracts inhibited COX-1 enzyme better than COX-2 enzyme. This may be 
because of the conformation of the active site of COX-1 which is smaller than that of 
COX-2 (MORITA, 2002). BOTTING (2006) pointed out that the smaller active site of 
COX-1 is more easily inhibited than the larger COX-2 site. However, it is undesirable 
to have good COX-1 activity because of the side effects in the gastrointestinal tract, 
which results in development of ulcers (LUSEBA, 2007). COX-2 have proven to be 
beneficial in clinical situations and led to the introduction of many potential anti-
inflammatory agents such as indomethacin, ibuprofen and piroxicam (MOLVI et al., 
2007). However, it was recently found that prolonged use of higher doses of COX-2 
selective inhibitors can cause side effects in humans, such as adverse 
cardiovascular effects (MOLVI et al., 2007; MODICA et al., 2005). According to 
NCUBE (2010), moderate active therapeutics may be used rather than high active 
ones, to reduce the manifestation of damaging side effects. 
 
The observed anti-inflammatory activities of the active extracts may be due to the 
overall effects of the plant constituents or the compounds having action similar to 
NSAID‘s, in a complimentary manner (ADEDAPO et al., 2008). Insignificant 
inhibition observed in some extracts in this study does not confirm inactivity of these 
extract as anti-inflammatory agents, the inactivity could be due to impurities or low 
concentrations of active compounds in the crude extracts or contain active 
compounds that act at other sites in the processes of pain and inflammation 
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Figure 1. Percentage inhibition of COX-1 and COX-2; Dichloromethane extracts (A), 
Petroleum ether extracts (B), 80% Ethanol extracts (C) and water extracts (D) by 12 
medicinal plants used by the Venda people against venereal diseases (1mg/ml). (1) Aloe 
chabaudii root, (2) Adansonia digitata bark, (3) Acacia karroo bark, (4) Bolusanthus 
speciosus leaf, (5) Bolusanthus speciosus bark, (6) Bolusanthus speciosus stem, (7) 
Elephantorrhiza burkei root, (8) Ekebergia capensis leaf, (9) Ekebergia capensis bark, (10) 
Grewia occidentalis root, (11) Osyris lanceolata leaf, (12) Osyris lanceolata root, (13) 
Peltophorum africanum bark, (14) Pterocarpus angolensis leaf, (15) Pterocarpus angolensis 
bark, (16) Pappea capensis leaf, (17) Ximenia caffra leaf, (18) Ximenia caffra root. Plant 
extracts with Inhibition activity above 70% were considered to be highly active. Percentage 
inhibition by positive controls indomethacin was 64.18 ± 3.10 and 68.50 ± 2.57 for COX-1 




3.3.2. HIV-1 RT inhibitory activity 
 
HIV infected people rely on antiretroviral drugs to improve the quality and prolong 
their lives. Antiretroviral drugs have many disadvantages including resistance, limited 
availability, high cost and lack of any curative effects (KLOS et al., 2009). Medicinal 
plants are an excellent source of anti-HIV agents (KLOS et al., 2009). In this study 
aqueous and methanolic extracts from twelve medicinal plants were tested for RT 
inhibition (Figure 2). The IC50 values of the plant extracts are shown in Table 6. Plant 
extracts with inhibitory activity above 70% were considered to be highly active 
(NDHLALA et al., 2010b). The inhibitory activity was also expressed as the half 
maximal inhibitory concentration (IC50). IC50 is a measure of the effectiveness of a 
compound in inhibiting biological or biochemical function (BHATTACHARJEE et al., 
2011). This measure indicates how much of a particular drug or other substance 
(inhibitor) is needed to inhibit a given biological process or component of a process 
(that is an enzyme, cell, cell receptor or microorganism) by half (BHATTACHARJEE 
et al., 2011).  
 
Methanol and water extracts of Acacia karroo bark, B. speciosus stems and X. caffra 
leaves and roots exhibited best inhibition percentages (>70%). Methanol extracts of 
A. chabaudi roots, E. capensis bark, and O. lanceolata roots showed low inhibition 
percentages. The smaller the IC50 value, the more potent the extract towards RT 
inhibition. The IC50 values show order of potency of the plants as: methanol extracts 
of A. karroo bark, B. speciosus stem and P. angolensis leaves > P. africanum bark 
and P. capensis > B. speciosus bark and water extracts of B. speciosus stem > E. 
capensis bark and P. angolensis leaves > B. speciosus leaves > G. occidentails 
roots and P. capensis leaves > A. digitata bark and P. africanum bark in that order 
are more potent inhibitors  of the RT. Except for methanol extracts of A. chabaudii 
roots, E. capensis bark and O. lanceolata roots, whose IC50 values could not be 
calculated because the activity was less than 50% at the highest concentration.  
 
A number of natural products are known for their activity against HIV-1 RT such as 
coumarins, flavonoids, tannins, alkaloids, lignans, terpenes, naphtho- and 
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anthraquinones, and polysaccharides (MATHÉE et al., 1999). Similar compounds 
were reported from B. speciosus (ERASTO et al., 2004; MAJINDA et al., 2001). 
Therefore the activity against HIV-1 RT from B. speciosus could be from these 
compounds.  The presence of acacatechin, catechutannic acid and quercetin in A. 
karroo may be responsible for the activity of this plant (VAN WYK et al., 2009). 
Ximenia caffra has been shown to contain simple phenolic compounds p-coumaric 
acid and ferulic acid (NDHLALA et al., 2008b), which inhibits HIV-1 protease activity 
(ICHIMURA et al., 1999). Water and methanol extracts of B. speciosus stem have 
great potential to be used as anti HIV-1 RT including methanol extracts of A. karroo 




































































Figure 2. Percentage inhibition of HIV-1 RT by 12 medicinal plants used by the Venda 
people against venereal diseases (1mg/ml). (1) Aloe chabaudii root, (2) Adansonia digitata 
bark, (3) Acacia karroo bark, (4) Bolusanthus speciosus leaf, (5) Bolusanthus speciosus 
bark, (6) Bolusanthus speciosus stem, (7) Elephantorrhiza burkei root, (8) Ekebergia 
capensis leaf, (9) Ekebergia capensis bark, (10) Grewia occidentalis root, (11) Osyris 
lanceolata leaf, (12) Osyris lanceolata root, (13) Peltophorum africanum bark, (14) 
Pterocarpus angolensis leaf, (15) Pterocarpus angolensis bark, (16) Pappea capensis leaf, 
(17) Ximenia caffra leaf, (18) Ximenia caffra root. Percentage inhibition by positive controls 














Table 6: HIV-1 RT inhibitory activity (IC50 mg/ml) of 12 medicinal plants used by the 
Venda people against venereal diseases 
Plant species Plant 
part 
HIV-1 RT inhibitory activity IC50 
(mg/ml)  
 
  Methanol extracts Water extracts 
Aloe chabaudii Root NC 0.60±0.06 
Adansonia digitata Bark 0.27±0.05 0.09±0.01 
Acacia karroo Bark 0.03±0.00 0.11±0.01 
Bolusanthus speciosus Leaf 0.43±0.04 0.07±0.01 
Bolusanthus speciosus Bark 0.07±0.00 0.16±0.02 
Bolusanthus speciosus Stem 0.03±0.00 0.03±0.00 
Elephantorrhiza burkei Root 0.52±0.00 0.37±0.03 
Ekebergia capensis Leaf 0.39±0.06 0.10±0.01 
Ekebergia capensis Bark NC 0.06±0.00 
Grewia occidentalis Root 0.91±0.32 0.08±0.01 
Osyris lanceolata Leaf 0.84±0.09 0.49±0.02 
Osyris lanceolata Root NC  0.49±0.02 
Peltophorum africanum Bark 0.05±0.01 0.09±0.01 
Pterocarpus angolensis Leaf 0.03±0.00 0.06±0.00 
Pterocarpus angolensis Bark 0.15±0.03 0.24±0.02 
Pappea capensis Leaf 0.05±0.00 0.08±0.00 
Ximenia caffra Leaf 0.41±0.05 0.37±0.02 
Ximenia caffra Root 0.15±0.01 0.21±0.02 
Combivir ®   0.06±0.03 
Kaletra ®   0.3±0.10 
 













The above results indicate that some of the tested plant extracts have potential to be 
used as enzyme inhibitors against venereal diseases.  
 
DCM and PE extracts of A. digitata bark, B. speciosus bark, P. angolensis bark and 
P. capensis leaves showed good anti-inflammatory activity in both COX-1 and COX-
2. Therefore these plants extracts may provide leads for the identification and 
isolation of active compounds for various inflammatory diseases.  
 
Numerous standard HIV therapies have been approved to treat HIV-infection; 
however some of these treatments have been reported to have side effect as well as 
being resistant to virus strains. Based on RT inhibitory activities observed in the 
present medicinal plants, methanol and water extracts of B. speciosus stems, P. 
africanum bark P. angolensis leaves and P. capensis leaves have good potential to 
be used as anti-HIV-1 RT inhibitors.  
 
This study has shown that the investigated medicinal plants could be harboring 
potent RT and inflammation inhibitors, opening up possibilities of compound 
isolation. However, more in vitro confirmatory tests using other assays and/or in vivo 













CHAPTER 4: Phytochemical Properties of twelve Medicinal 
plants that are used by Venda people against Venereal and 
related diseases 
 
4.1. Introduction  
 
Plants produce a vast range of compounds that are traditionally classified as either 
primary or secondary metabolites. Primary metabolites are compounds that have 
essential roles associated with photosynthesis, respiration, growth and development. 
Plant secondary metabolites are a diverse group of molecules that are involved in 
the adaption of plants to their environment and are not involved in primary 
metabolism (MAKKAR et al., 2007).  
 
Secondary metabolites (often referred to as phytochemicals) are either present in the 
plant in active states or as prodrugs that becomes activated upon wounding, 
infection or in the body of herbivores (WINK, 1999; 2003). Being sessile organisms, 
plants cannot run away when they are attacked by herbivores or microbial infections 
(WINK, 1999; 2003). Plants have thus developed secondary biochemical pathways 
to synthesize a range of chemicals, often responding to specific environmental 
stimuli, such as herbivore-induced damage, pathogen attacks, or nutrient 
deficiencies (KENNEDY and WIGHTMAN, 2011). The largest and most prevalent 
phytochemical groups are the alkaloids, terpenes and phenolic compounds 
(KENNEDY and WIGHTMAN, 2011).  
 
Secondary metabolites have been used for centuries in traditional medicine because 
of their diverse biological activities. Nowadays secondary metabolites are used as a 
basis for the production of valuable synthetic compounds such as pharmaceuticals, 
cosmetics, or more recently nutraceuticals (BOURGAUD et al., 2001). They are also 
viewed as potential sources of new natural drugs, antibiotics, insecticides and 
herbicides (CROZIER et al., 2006). Due to their biological significance and potential 
health effects, such as antioxidant, anticancer, anti-aging, anti-atherosclerotic, 
antimicrobial, and anti-inflammatory activities, phytochemicals have gained 
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increasing attention from researchers (SHAHIDI, 2004; SHAHIDI et al., 2008).  
Regular intake of some phytochemicals have been reported to reduce risks of 
chronic diseases, such as cancer, heart attack and diabetes (ZHU et al., 2009). 
 
4.1.1. Phenolic compounds 
 
Phenolic compounds are among the largest groups of secondary metabolites that 
are ubiquitously found across the plant kingdom, with approximately 10,000 
structures (GURIB-FAKIM, 2006; KENNEDY and WIGHTMAN, 2011). Phenolic 
compounds range from simple low-molecular weight compounds, with one aromatic 
ring such as the simple phenylpropanoids, coumarins, and benzonic acid derivatives, 
to complex structures such as tannins, flavonoids, stilbenes, and lignins (GURIB-
FAKIM, 2006; CROZIER et al., 2006; KENNEDY and WIGHTMAN, 2011). 
 
Flavonoids represent the largest, most diverse group of phenolic compounds, 
encompassing some 6000 compounds (KENNEDY and WIGHTMAN, 2011). 
Flavonoids can be divided into sub-groups namely: flavones, flavonols, flavanones, 
isoflavones, flavan-3-ols, and anthocyanins (CROZIER et al., 2006; KENNEDY and 
WIGHTMAN, 2011). The generic flavonoid structure is shown in Figure 3. They are 
generally found in fruits, vegetables, nuts, seeds, stems, cereals, legumes, herbs, 
spices, and flowers as well as tea, wine, propolis, and represent a common 
constituent of the human diet (KANDASWAMI et al., 2005; CUSHNIE and LAMB, 
2005). Tannins are a very complex group of secondary metabolites capable of 
tanning leather or precipitating gelatin from solution, a property known as 
astringency (COWAN, 1999; SILANIKOVE et al., 2001). Their molecular weights 
range from 500 to 3,000 and are broadly found in every plant part: bark, wood, 
leaves, fruits, and roots (COWAN, 1999). Tannins are found in approximately 80% of 
woody and 15% of herbaceous dicotyledonous species (SILANIKOVE et al. 2001). 
They are divided into two groups, hydrolyzable and condensed tannins (COWAN, 
1999; GURIB-FAKIM, 2006). The structure of hydrolyzable and condensed tannins 
















Figure 3. Generic structure of flavonoids in which rings A, B, and C and the numbering 
system are shown. Kaempferol, R1 = H, R2 = H quercetin, R1 = OH, R2 = H; myricetin, R1= 


































Figure 4. Structures of (A) penta galloyl-D-glucose (hydrolyzable tannin) and (B) 
proanthocyanidin (condensed tannin), where ‗n‘ is any number that makes up the polymer. 
Structures adapted from (CROZIER et al., 2006) 
 
4.1.2. Medicinal properties of phenolic compounds 
 
Flavonoids have been reported to possess several pharmacological properties 
(HAVSTEEN, 1983; HARBORNE and BAXTER, 1999; KANDASWAMI et al., 2005; 
CUSHNIE and LAMB, 2005). Their enzyme inhibitory properties have been 
assumed to be due to the interaction of enzymes with different parts of the flavonoid 
molecule, e.g. carbohydrate, phenyl ring, phenol and benzopyrone ring (CUSHNIE 
and LAMB, 2005). Because of the above properties, flavonoids have now 
increasingly become the subjects of medical research. Several flavonoids are known 
to inhibit HIV-1 including demethylated gardenin A, robinetin, myricetin, baicalein, 
quercetagetin and quercetin (CUSHNIE and LAMB, 2005). Flavonoids such as 
quercetin inhibit both cycloxygenases and lipoxygenases by reducing the release of 
arachidonic acid (HARBORNE and WILLIAMS, 2000; NIJVELDT et al., 2001). 
Several studies have reported tannins to have medicinal properties, such as 
antimicrobial, antifungal, anti-inflammatory, antiviral, anti-diarrhoeal, anti-cancer 
activities as well as inhibition of HIV replication and human simplex virus by 
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interacting well with enzymes (proteins) within cell systems (HASLAM, 1996; 
OKUDA, 2005; COWAN, 1999; GURIB-FAKIM, 2006). According to VANDEN et al. 
1985 tannins act principally by binding to the virus and/or the protein of the host cell 
membrane and therefore arrest absorption of the virus. The relevant physiological 
effects of tannins on herbivores is their ability to complex with proteinaceous material 
such as their complexation with metal ions, their antioxidant and radical scavenging 
activities and their ability to complex with other molecules including macromolecules 
such as proteins and polysaccharides (HASLAM, 1988; HASLAM, 1996).  
 
Twelve medicinal plants used by the Venda people against venereal diseases were 
evaluated for their levels of phenolic content including flavonoids, gallotannins and 
condensed tannins.  
 
4.2. Materials and Methods 
 
4.2.1. Plants collection and sample preparation 
 
The plants were collected and prepared as described in Section 2.3.1. of Chapter 2.  
 
4.2.2. Determination of phenolic contents 
 
4.2.2.1. Preparation of extracts 
 
Phenolic compounds were extracted from plant material as described by MAKKAR 
(1999) with modification. Dried plant samples (2 g) were extracted with 10 ml of 50% 
aqueous methanol by sonication in a cold water bath for 20 min. The extracts were 
then filtered under vacuum through Whatman No.1 filter paper and stored in dark 







4.2.2.2. Determination of total phenolics 
 
The amounts of total phenolics in plant samples were determined using the Folin 
Ciocalteu (Folin C.) method for total phenolics as described by MAKKAR (1999) with 
slight modification (NDHLALA et al., 2007). Folin-C reagent (2N) (Sigma-Aldrich, 
USA) was made up with an equal volume of distilled water in a dark bottle, to obtain 
a 1N Folin-C reagent required for the assay. Standard gallic acid (Sigma-Aldrich, 
USA) solution was prepared in water at 0.1 mg/ml. Fifty microlitres of each plant 
methanolic extract were transferred into test tubes and 950 µl distilled water were 
added to make up to 1 ml, followed by 1 N Folin-C reagent (500 µl) and 2% sodium 
carbonate (2.5 ml). A blank that contained 50% aqueous methanol instead of plant 
extracts was also prepared. The test mixtures were incubated for 40 min at room 
temperature and absorbance was read at 725 nm using a UV-visible 
spectrophotometer (Varian Cary 50, Australia). Each plant extract was assayed in 
triplicate. Total phenolic concentrations were expressed as gallic acid (GAE) 
equivalents. 
 
4.2.2.3. The butanol-HCl assay for condensed tannins 
 
Three millilitres of butanol-HCl reagent (95:5 v/v) were added to 500 µl of each 
methanolic extract, followed by 100 µl ferric reagent (2% ferric ammonium sulphate 
in 2N HCl). The test combination was mixed by vortexing and placed in a boiling 
water bath for 60 min. The absorbance was then read at 550 nm using a UV-visible 
spectrophotometer (Varian Cary 50, Australia) against a blank prepared by mixing 
extract (500 µl) with butanol-HCl reagent (3 ml) and ferric reagent (100 µl), but 
without heating. Each extract had three replicate. Condensed tannin (% per dry 
matter) was calculated as equivalent amounts of leucocyanidins (LE) using the 
formula developed by PORTER et al. (1986): Condensed tannin = (A550 nm × 78.26 
× dilution factor) ∕ (% dry matter)Where A550 nm is the absorbance of the sample at 





4.2.2.4. Rhodanine assay for gallotannins 
 
The determination of hydrolysable tannin as gallotannins was done according to 
MAKKAR (1999) with modifications (NDHLALA et al. 2007). Plant extracts (50 µl) 
were made up to 1 ml with distilled water. One hundred microlitres of 0.4 N sulphuric 
acid and 600 µl rhodanine were added to the diluted extracts. After 5 min at room 
temperature, 200 µl of 0.5 M potassium hydroxide were added followed by 4 ml 
distilled water after a further 2.5 min. The mixtures were left for a further 15 min at 
room temperature, after which the absorbance at 520 nm was read using a UV-
visible spectrophotometer (Varian Cary 50, Australia) against a blank test tube that 
contained 50% aqueous methanol instead of sample. Each extract was evaluated in 
triplicate and gallotannin concentrations were expressed as gallic acid (GAE) 
equivalents.  
 
4.2.2.5. Vanillin assay for flavonoids 
 
The flavonoid content was evaluated as described by HAGERMAN (2002) with 
modifications. Plant extracts (50 µl) (in triplicate), were made up to 1 ml with 
methanol in test tubes before adding 2.5 ml methanolic-HCl (95:5 v/v) and 2.5 ml of 
1% vanillin reagent (1g/100 ml in glacial acetic acid) in methanol. Similar 
preparations of a blank that contained methanol instead of plant extracts were made. 
After 20 min at 30 °C, absorbance at 500 nm was read using a UV-visible 
spectrophotometer (Varian Cary 50, Australia). A catechin standard curve was 
prepared from a freshly made 1 mg/ml catechin (Sigma-Aldrich) stock solution in 
methanol. The amount of flavonoids in the plant extracts were expressed as catechin 











4.3. Results and discussion 
 
4.3.1. Phenolic content 
 
Phenolic compounds are ubiquitous in plants but the type of compound present 
varies considerably according to the phylum under consideration (LATTANZIO et 
al., 2006). To protect plants against microbial invasion phenolic compounds form an 
integral part of the cell wall structure in the form of polymeric material such as lignin. 
Its role is to provide mechanical strength and to response to stress and pathogens 
(GORSHKOVA et al., 2000). Plant phenolic compounds have been reported to have 
several medicinal properties such as antimicrobial, anti-flamatory, anti-diabetic, anti-
carcinogenic, antineoplastic effects and antiviral activities (HAVSTEEN, 1983; 
HARBORNE and BAXTER, 1999; KANDASWAMI et al., 2005; CUSHNIE and 
LAMB, 2005). Due to these pharmacological properties, plant phenolic compounds 
have gained increasing attention in both modern and traditional medicine as 
therapeutic compounds. 
 
The total phenolic levels of the plant species in this study are shown in Table 7. 
Phenolic compounds amounting to 4.5% of the dry matter of plant extracts are 
considered to be significantly high and have beneficial effects such as antioxidant 
activity (MAKKAR, 2003; MAKKAR et al., 2007). Almost all extracts contained total 
phenolic compounds greater than 5 mg/g for A. chabaudii roots and A. digitata bark 
which had lower levels (< 5 mg/ml). The same plants exhibited poor antimicrobial 
activities (Chapter 2). However, A. digitata showed good COX and HIV-1 RT 
enzyme inhibition (Chapter 3) except for the water extracts towards both COX-1 and 
2.  
 
The highest levels of flavonoids (11.9 and 11.1 µg/g) were detected in X. caffra 
leaves and roots, A. karroo bark (7.7 µg/g) and P. angolensis bark (8.34 µg/g) with 
the lowest amounts being recorded in A. chabaudii roots, A. digitata bark, B. 
speciosus bark, leaves and stems and P. angolensis leaves Table 7. Flavonoids are 
known to have activity against cycloxygenases and lipoxygenases (LOX) as well as 
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HIV-1 RT (HARBORNE and WILLIAMS, 2000; MATHÉE et al., 1999). Ximenia 
caffra leaves and A. karroo bark exhibited best COX-1 and HIV-1 RT enzyme activity 
in both leaves and roots of X. caffra (Chapter 3). P. angolensis bark showed good 
enzyme inhibition against COX-1 and 2 and HIV-1 RT enzyme (Chapter 3). 
Flavonoids have many beneficial health effects for human beings and several 
studies have shown that intake of flavonoids improves health and fights off chronic 
diseases (PAN et al., 2010). It have been shown that they have anti-inflammatory 
activity through several action mechanisms which involve the reduction in the 
concentration of prostanoids and leukotrienes, through the inhibition of eicosanoid 
generating enzymes such as phospholipase, COX and LOX (CALDER et al., 2009). 
The amount of flavonoids recorded in these plants may have probably contributed to 
the observed antimicrobial and enzyme inhibitory activity.  
 
BOJASE et al. (2002) and ERASTO et al. (2004) isolated flavonoids from extracts 
of B. speciosus with strong antimicrobial activity against E. coli, B. subtilis, S. aureus 
and Candida mycoderma from different plant parts. However, in this study, low 
amounts of flavonoids were recorded in the leaves, bark and stems of the B. 
speciosus. This suggests that it could be quality rather than quantity that matters on 
the potency of phenolic compounds and also geographical area or where plants 
were collected.  
 
Gallotannins exhibit some biological activities including antimicrobial, anticancer, 
anti-inflammatory and antiviral properties (HAGERMAN et al., 1999; VAN MOLLE et 
al., 2000; FELDMAN et al., 2001; LEE et al., 2003). Amounts of gallotannin present 
in the investigated plant extracts are shown in Table 7. The highest amounts of 
gallotannin were detected in E. capensis bark (70.0 µg/g), P. africanum bark (60.1 
µg/g) and P. angolensis bark (64.0 µg/g). Aqueous alcohols such as methanol are 
the best solvents to extract tannin (MAKKAR, 1999). In this study, ethanol extracts 
of E. capensis bark showed good antibacterial activity as well as enzyme inhibition 
against COX-1. Ethanol extracts of P. africanum bark and P. angolensis bark 
showed good antibacterial activity as well as enzyme inhibition against COX-1 and 
HIV-1 RT enzymes (Chapter 2 and Chapter 3). It is possible that gallotannins 
contributed to pharmacological activities of these plants. Very low levels of 
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gallotannins were detected in A. chabaudii roots, A. digitata bark and B. speciosus 
stems. 
 
The highest amounts of condensed tannins were detected in E. capensis bark, X. 
caffra roots and A. karroo bark (0.470, 0.476 and 0.42 %) respectively Table 7. 
Condensed tannins were not detected in B. speciosus bark, B. speciosus stems, P. 
angolensis leaves and P. angolensis bark. According to BRUNETON (1995), tannins 
enhance tissue regeneration in superficial wounds or burns, and have demonstrated 
antiseptic effects (antibacterial and antifungal). Therefore, the tannins present in E. 
capensis bark and X. caffra roots may have been responsible for the activity against 
some of the tested bacteria, C. albicans and the activity against some of the enzyme 
inhibitions reported in this study. Low amount of tannins and low antimicrobial 
activities and enzyme inhibition in some plants could be due to the interaction of 
tannins with protein and other biological macromolecules. 
 
Tannin constituents reduce the mutagenicity of a number of mutagens and have 
anticarcinogenic, antimicrobial and anti-HIV activities, which are beneficial to 
humans (LIAO and SHI, 2005). However, there is evidence that tannins, especially 
hydrolyzable tannins produce adverse effects in certain animals and humans such 
as perturbation of mineral adsorption from the intestinal canal, a decrease in body-
weight, growth retardation and inhibition of digestive enzymes (LIAO and SHI, 
2005). In addition, some phenolic compounds have been reported to impact 
negatively on physiological effects such as neurological problems, reproductive 
failure, goitre and in more severe cases may lead to death when consumed in higher 
concentrations (MAKKAR et al., 2007). However, high amounts of phenolic 
compounds in some plants may result in good pharmacological benefits. Examples 
include tannins in E. capensis bark and A. karroo bark as well as flavonoids in A. 
karroo and X. caffra. Different amount of phenolic content were detected in different 
plant part. According to SULTANA et al. (2007) phenolic compounds are not evenly 
distributed in plants part; they are present at elevated amounts in out parts of the 
fruits, leaves and barks. However in this study the amount of phenolic content in 
leaves and bark are present in Low/high amount depending on plant part, this could 






It is a possibility that some phenolic groups detected as part of the total phenolics 
are not flavonoids, gallotannins or condensed tannin in nature but, other types such 
as simple phenylpropanoids, coumarins and benzoic acid derivatives. For example 
lower amounts of phenolic compounds are detected in A. digitata bark in all assays 
but the same plant exhibited good inhibition against COX and HIV-1 RT enzymes 
(Chapter 3). The activities could be from other types of phenolic compounds such as 
terpenoids, apart from the tested ones (SHAHAT, 2006).  
 
In this study some plant extracts exhibited good activities but with low amounts of 
phenolic compounds such as B. speciosus and A. digitata bark. It could be possible 
that the activity observed could be from other secondary metabolites apart from 






Table 7: Total phenolics, flavonoid, gallotannin and condensed tannin concentrations of 12 medicinal plants used by the Venda 
people against venereal diseases 
 
aValues expressed as gallic acid equivalent ( GAE) per gram of plant extracted; 
bValues expressed as catechin equivalents (CTE) per gram of plant extracted ; 
















Aloe chabaudii Root 2.20±0.14 0.19±0.03 4.21±0.54 0.09±0.04 
Adansonia digitata Bark 2.43±0.04 0.25±0.06 2.85±0.11 0.03±0.03 
Acacia karroo Bark 12.11±0.08 7.74±0.16 30.54±9.81 0.42±0.01 
Bolusanthus speciosus Leaf 10.49±0.11 0.20±0.01 5.84±0.42 0.04±0.02 
Bolusanthus speciosus Bark 8.69±0.56 0.04±0.00 4.50±1.50 0.00±0.00 
Bolusanthus speciosus Stem 10.44±0.67 0.25±0.02 3.07±0.27 0.00±0.00 
Elephantorrhiza burkei Root 11.97±0.06 3.71±0.47 31.59±1.34 0.38±0.01 
Ekebergia capensis Leaf 12.02±0.06 1.48±0.08 35.37±1.88 0.32±0.02 
















Grewia occidentalis Root 11.67±0.10 1.24±0.14 13.20±1.15 0.18±0.07 
Osyris lanceolata Leaf 11.90±0.07 3.94±0.23 19.18±3.21 0.30±0.02 
Osyris lanceolata Root 12.04±0.04 3.73±0.16 47.34±2.18 0.22±0.02 
Peltophorum africanum Bark 12.15±0.03 4.14±0.15 60.29±5.60 0.24±0.01 
Pterocarpus angolensis Leaf 8.85±0.10 0.29±0.00 7.11±0.88 0.00±0.00 
Pterocarpus angolensis Bark 12.07±0.08 8.34±0.13 64.00±9.09 0.00±0.00 
Pappea  capensis Leaf 12.05±0.09 1.65±0.04 9.50±1.18 0.28±0.01 
Ximenia  caffra Leaf 11.87±0.08 11.88±0.04 40.41±1.65 0.15±0.01 
Ximenia caffra Root 11.95±0.01 11.06±0.18 26.92±4.21 0.48±0.03 
 
aValues expressed as gallic acid equivalent ( GAE) per gram of plant extracted; 
bValues expressed as catechin equivalents (CTE) per gram of plant extracted ; 








Plant secondary metabolites act as defense mechanisms against herbivores, 
pathogenic attack and nutrient deprivation. The observed antibacterial results of 
some species in this study correspond with high amounts of phenolic compounds for 
examples X. caffra. This suggests that there exists a correlation between high 
antimicrobial properties and high phenolic composition.  
 
High levels of phenolics, flavonoids, gallotannins and condensed tannins were 
detected in X. caffra species. The high levels of phenolic compounds may have been 
responsible for the high antimicrobial activities and enzyme inhibition observed for 
extracts of X. caffra. Adansonia digitata bark and A. chabaudii exhibited poor 
antimicrobial activities as well as low amounts of phenolic compounds. Bolusanthus 
speciosus showed good pharmacological activities with low amounts of flavonoids, 
gallotannins and condensed tannins. In view of the biological activity observed in this 
study, assessment of other groups of phytochemical compounds and evaluating both 
















CHAPTER 5: Mutagenicity Evaluation of twelve Medicinal 
plants used by the Venda people against Venereal and 




Natural products research has an important role in the discovery of novel 
compounds for drug development (NEWMAN et al., 2000). Many of these products 
are consumed with little or no evidence of pharmacological properties and/or safety 
knowledge (CÂNDIDO-BACANI et al., 2011). Plants produce secondary metabolites 
as defense compounds against herbivores, micro-organisms and viruses. It is 
estimated that around 750 poisonous substances occur in more than 1000 species 
used (WINK and VAN WYK, 2008). The plants should therefore be used with 
caution and with an appreciation of their toxicity risks (CÂNDIDO-BACANI et al., 
2011).  
 
Traditional medicinal plants are reported to be effective in treating many infectious 
diseases. Despite the therapeutic advantages, some of the plants have been shown 
to be potentially toxic, carcinogenic and teratogenic (AKINBORO and BAKARE, 
2007; DE SÁ FERREIRA and VARGAS, 1999). Many plants used as food or in 
traditional medicine have been shown to have mutagenic effects by in vitro assays 
(SCHIMMER et al., 1994, KASSIE et al., 1996 and DEMMA et al., 2009). It is 
important to assess the cytotoxic and mutagenic potential to ensure a relatively safe 
use of plant-derived medicines (CAVALCANTI et al., 2006). This assessment can 
be used for potential chemotherapeutic drugs and as a measure of safety for the 
continued long term use of medicinal plants (VERSCHAEVE et al., 2004). 
 
Toxicity occurs when a substance exerts negative effects on an organism and its 
metabolism. In animals and humans, it interferes with central functions of an 
organism. For example, neurotoxins affect the brain and the nervous system, while 
cytotoxins and metabolic poisons disturb the liver, kidneys, heart or the respiratory 




5.1.1. Mutagenicity  
 
Mutagenicity is a result of substances that induce genetic mutations leading to 
alteration or loss of genes or chromosomes (WINK and VAN WYK, 2008).  
Mutagens include physical agents such as ultra violet (UV) and X-rays which cause 
the deletion of nucleotides. Mutagens produce a variety of lesions in DNA, as well as 
strand break, base damage and dimerisation of bases. A range of diverse 
environmental, industrial, dietary and natural chemicals are capable of inducing 
mutations and genotoxic effects (BHATTACHARYA, 2011).  Gene mutations that 
cause changes in growth requirements can easily be detected in bacteria, while 
chromosome damage in mammalian cells is typically measured by observing the 
cell‘s chromosomes under magnification for breaks or rearrangements 
(MORTELMANS and ZEIGER, 2000).    
 
5.1.2. Effects of mutagenicity in humans 
 
Chemicals that are capable of inducing mutations can potentially damage the germ 
line leading to fertility problems, cancer and even mutations in future generations. 
DNA damage by environmental mutagens can be a cause of disability in many 
animals, including humans (CARIÑO-CORTÉS et al., 2007). Mutation events are 
involved in several degenerative diseases, such as cancer and arteriosclerosis as 
well as aging, and genetic defects in the offspring (DE FLORA, 1998; CARIÑO-
CORTÉS et al., 2007). This concern has driven most of the mutagenicity testing 
programs. Identification of the substances that are capable of inducing mutations has 
become an important procedure in safety assessments (MORTELMANS and 
ZEIGER, 2000). 
 
5.1.3. Ames test 
 
The Ames test (Salmonella typhimurium/microsome assay) is widely used as a 
short-term bacterial assay for identifying substances that can produce genetic 
damage leading to mutations (MORTELMANS and ZEIGER, 2000). It is also used 
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worldwide by regulatory agencies as an initial screen to determine the mutagenic 
potential of new chemicals and drugs (MORTELMANS and ZEIGER, 2000; 
HAKURA et al., 2005). This test uses several Salmonella strains with pre-existing 
mutations that leave the bacteria unable to synthesize the essential amino acid 
histidine and therefore are unable to grow and form colonies in the absence of this 
amino acid. New mutations on the pre-existing mutations can restore the gene 
function and allow the cells to synthesize histidine. Newly mutated cells can grow in 
the absence of histidine and form colonies (MORTELMANS and ZEIGER, 2000). 
The assay therefore, utilizes this principle to assess if the drugs/extracts are capable 
of reverting the mutations to restore the normal functions and colony formation in 
these bacterial strains. 
 
5.1.3.1. Oxidative metabolism 
 
Many carcinogens such as aromatic amines or polycyclic aromatic hydrocarbons 
remain inactive until they are enzymatically transformed to an electrophilic species 
that is capable of covalently binding to DNA leading to mutation; thus, metabolic 
activation is considered to be a critical step in mutation (AMES et al., 1973; 
MORTELMANS and ZEIGER, 2000). The cytochrome-based P450 metabolic 
oxidation system, present mainly in the liver and to a lesser extent in the lung and 
kidneys of humans and lower animals, is capable of metabolizing a large number of 
these chemicals to DNA-reactive, electrophilic forms. Some of the intermediate 
metabolites are potent mutagens in the Ames Salmonella assay. Since bacteria do 
not have this metabolic capability, an exogenous mammalian organ (such as liver or 
kidney) activation system needs to be added to the Petri plate together with the test 
chemical and the bacteria (MORTELMANS and ZEIGER, 2000). A metabolic 
activation system usually consists of a 9000 x g supernatant fraction of rat liver 
homogenate (S-9 microsomal fraction) (MORTELMANS and ZEIGER, 2000). 
 
Studies on the properties of phytotherapeutic agents, including studies on mutagenic 
and anti-mutagenic activities correlated with the presence of certain substances 
found in herbal medicine, has steadily increased, covering groups of flavonoids, 
tannins and alkaloids (RIETJENS et al., 2005; HORN and VARGAS, 2008). 
Research by CARDOSO et al. (2006), DÉCIGA-CAMPOS et al. (2007) and MOHD-
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FUAT et al. (2007) have shown that a lot of plants used in traditional medicine have 
in vitro mutagenic or toxic and carcinogenic properties. According to VERSCHAEVE 
and VAN STADEN (2008), it is important to screen medicinal plants for their 
mutagenic potency. Therefore, in this study, the mutagenic effect of selected 
medicinal plants that are used against venereal and related diseases by Vha-Venda 
people was determined using the Ames test.  
 
5.2. Materials and Methods 
 
Mutagenicity was tested using the Salmonella microsome assay as described by 
MARON and AMES (1983) with modification by MORTELMANS and ZEIGER 
(2000). Dichloromethane, PET, EtOH and water extracts were tested for their 
potential mutagenic properties using the plate-incorporation procedure with 
Salmonella typhimurium tester strain TA98 with and without metabolic activation. 
Overnight bacterial tester strains were cultured in  10 ml Oxoid nutrient broth No. 2 
for 16 h at 37 °C to obtain a density of 1-2 x 109 colony forming units (CFU/ml). The 
metabolic activation mixture (S-9 mix) was prepared freshly before the assay and 
kept on ice throughout the assay procedure. The S9 mix consisted of 5% (v/v) S9 
fraction (Sigma-Aldrich, Co., St Louis) pooled from Sprague-Dawley male rats in 
mixed enzymic cofactors containing NADP. At the beginning of the assay, top agar 
supplemented with 0.5 mM histidine and biotin was melted and kept in a 50 °C water 
bath. To sterile glass tubes, in triplicate, 100 µl of  three dilutions (50, 500, 5000 
µg/ml) per sample were added, followed by 500 µl phosphate buffer (0.1 mM, pH 
7.4) or S9 mix. To the mixture, 100 µl of the overnight bacterial culture were added 
followed by 2 ml of the melted top agar. The contents of the tubes were then mixed 
and poured onto labelled minimal agar plates (minimal agar is agar that contains 
minimum nutrients such as glucose). As soon as the top agar had hardened (2-3 
min), the plates were inverted and incubated at 37 °C for 48 h. The colonies were 
then counted with the aid of a binocular microscope. The assay was repeated twice 
for TA98 bacterial strain and the results were expressed as the mean (± standard 
error) number of revertant colonies per plate. 4-Nitroquinoline-N-oxide (4NQO) (2 
µg/plate) was used as a positive control for the assay without metabolic activation 
while 2-aminoanthracene (2-AA) (2 µg/plate) was used where the assay was carried 
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out with S9 metabolic activation. Sterile distilled water was used as a negative 
control in both assays. The test extracts/compound was classified as a ‗mutagen‘ if 
the results satisfied two criteria: (1) a dose dependent increase in the number of 
revertants is observed and (2) the number of His+ (histidine) revertants is equal or 
greater than two times that of the negative control. 
 
5.3. Results and discussion 
 
The results of the evaluated medicinal plants are shown in Table 8. The results 
represent the number of His+ revertants with and without S9+ against Salmonella 
typhimurium tester strains TA98 in three dilutions. TA98 strains have a -1 frameshift 
mutation at hisD3052 which affects the reading frame of a repetitive base pair –C-G-
C-G-C-G-C-G- sequence. The reversion of the hisD3052 mutation back to the wild-
type state is induced by various frameshift mutagens such as 2-nitrofluorene and 
various aromatic nitroso derivatives of amine carcinogens (MORTELMANS and 
ZEIGER, 2000). 
 
Ames test without S9 metabolic activation detects direct mutagens. In this study, all 
plants were non-mutagenic towards TA98 without S9 activation in both organic and 
inorganic extracts. The numbers of revertants were less than that of the negative 
control. However, if the number of revertant colonies is far below the negative control 
(spontaneous reversion) it is classified as toxic (NDHLALA et al., 2010a).  
 
Ames test with S9+ metabolic activation allows the detection of indirect mutagens. All 
the samples were not mutagenic after S9 activation. The only exceptions were E. 
burkei roots and E. capensis bark that showed indirect mutagenic effects toward 
TA98 in water extracts. Elephantorrhiza burkei roots induce indirect mutagenic 
effects at 500 µg/ml and 50 µg/ml (53.5 and 58.0 µg/ml respectively). Ekebergia 
capensis bark induced 50.0 revertant colonies at 500 µg/ml and 50 µg/ml. However, 
there is no dose dependent increase; this does not satisfy the first condition for a 
mutagen which states that an extracts/compound should have a dose dependent 
increase in colonies. These plant extracts showed weak mutagenicity. Therefore it is 
important to increase the concentration to check if there is increase in the number of 
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revertants colonies which confirm mutagenicity on these plants.  Elephantorrhiza 
burkei roots and E. capensis bark could contain some frameshif mutagens.  
 
The water extract of E. burkei roots and E. capensis bark exhibited good 
antimicrobial and enzyme inhibition activities. The highest amounts of condensed 
tannins and gallotannins were recorded in E. capensis bark. Ekebergia capensis 
contain bioactive chemical compounds such as glycosides, polyphenols, tannins, 
triterpenes and saponins (SEWRAM et al., 2000). Tannins, especially hydrolysable 
tannins produce adverse effects in certain animals and humans (LIAO and SHI, 
2005). Mutagenic effects in these plants could be from phenolic compounds. 
However, some tannin constituents reduce the mutagenicity of a number of 
mutagens and have anticarcinogenic, antimicrobial and anti-HIV activities, which are 
beneficial for humans. 
 
The tested medicinal plants are used for the treatment of different ailments including 
venereal diseases and have shown promising biological activities in different studies. 
Therefore further toxicity tests need to be done as the Ames test with S9+ has 






Table 8: Number of His+ revertants in Salmonella typhimurium strains TA98 (preparations with and without S9 metabolic activation) 
of 12 medicinal plants used by the Venda people against venereal diseases 
Number of His+ revertants 
   PET   DCM   EtOH  Water   
Plant species Plant parts µg/ml S9- S9+ S9- S9+ S9- S9+ S9- S9+ 
Aloe chabaudii Root 5000 16.7±5.2 18.0±5.0 12.0±1.0 20.5±3.5 14.3±0.7 39.5±8.5 15.0±0.0 29.0±7.0 
  500 18.7±2.0 22.0±1.0 17.0±3.2 24.0±4.0 16.0±1.0 27.0±6.0 11.0±0.0 28.0±2.0 
  50 15.3±0.9 23.0±0.0 16.3±0.7 19.0±5.0 21.0±1.0 29.0±9.0 15.3±1.7 28.5±1.5 
           
Adansonia digitata Bark 5000 13.7±0.3 20.5±1.5 18.0±2.0 22.5±3.5 16.3±0.3 15.5±0.5 13.0±1.0 32.5±3.5 
  500 16.3±1.3 24.5±0.5 14.7±1.2 27.5±3.5 17.0±3.2 16.0±1.0 15.3±1.5 24.5±2.5 
  50 16.3±1.9 22.5±1.5 17.0±1.5 26. 5±4.5 19.0±2.1 18.0±0.0 13.0±1.0 29.0±1.0 
           
Acacia karroo Bark 5000 17.0±2.1 22.5±2.5 15.7±1.3 26.5±6.5 19.7±2.4 12.5±1.5 14.3±1.8 27.0±6.0 
  500 23.0±3.2 20.5±4.5 16.3±1.7 21.5±1.5 18.0±1.2 15.0±2.0 12.0±1.0 31.0±1.0 
  50 19.3±3.0 30.0±2.0 14.3±1.3 31.5±6.5 15.3±1.3 17.0±1.0 14.7±1.3 31.0±0.0 
           
Bolusanthus speciosus Leaf 5000 13.3±0.3 22.0±0.0 15.3±0.3 24.0±2.0 14.3±1.3 18.0±4.0 14.3±1.7 31.0±1.0 
  500 16.3±3.8 21.5±0.5 13.0±1.0 29.0±4.0 16.7±0.3 14.5±1.5 11.3±0.3 20.0±5.0 
  50 15.3±2.7 20.0±1.0 12.7±1.9 22.0±1.0 17.0±0.0 17.5±1.5 15.0±0.0 29.0±0.0 
 
Number of His+ revertants/plate: mean values of three triplicates, the assay was repeated two times 
S9- refers to assay without metabolic activation; S9+ refers to assay with metabolic activation 






Table 8: Continuation 
Number of His+ revertants 
   PET   DCM   EtOH  Water   
Plant species Plant parts µg/ml S9- S9+ S9- S9+ S9- S9+ S9- S9+ 
Bolusanthus speciosus Bark 5000 12.0±1.0 21.5±0.5 15.7±1.3 25.0±3.0 19.0±3.5 19.0±1.0 14.3±1.7 23.0±1.0 
  500 16.0±2.1 23.5±1.5 17.7±0.3 24.5±2.5 17.3±0.3 11.5±0.5 11. 7±0.3 22.5±2.5 
  50 14.7±1.7 20.0±0.0 15.3±1.9 29.0±6.0 19.0±0.0 15.5±0.5 15.0±0.0 28.5±3.5 
           
Bolusanthus speciosus Stem 5000 14.0±1.2 17.0±4.0 15.3±0.3 24.0±6.0 23.0±1.0 23.5±5.5 15.7±0.7 43.5±4.5 
  500 16.0±1.0 29.0±1.0 15.0±2.6 24.0±2.0 18.0±1.5 35.0±5.0 14.3±2.3 23.0±2.0 
  50 17.0±1.0 25.0±1.0 17.3±0.3 25.5±1.5 15.7±0.3 19.0±1.0 12.0±0.0 42.5±0.5 
           
Elephantorrhiza burkei Root 5000 16.3±0.3 31.0±2.0 16.7±0.3 16.0±1.0 16.0±0.6 11.5±2.5 14.7±1.5 53.5±13.5 
  500 15.0±2.0 25.0±7.0 15.7±2.3 21.0±0.0 17.7±1.2 16.5±1.5 15.0±1.7 24.0±0.0 
  50 15.3±1.3 25.5±0.5 17.0±3.5 22.5±1.5 24.7±1.5 15.5±0.5 13.0±2.0 58.0±8.0 
           
Ekebergia capensis Leaf 5000 14.3±1.8 25.5±1.5 15.0±1.2 17.5±3.5 15.7±2.4 15.5±1.5 13.7±1.8 40.0±7.0 
  500 19.7±1.2 23.0±0.0 14.3±0.3 22.5±2.5 16.7±2.2 13.0±3.0 15.0±3.0 48.0±6.0 
  50 14.7±1.9 22.5±0.5 11.3±0.3 19.5±2.5 13.7±2.3 16.5±0.5 12.7±0.7 39.0±6.0 
 
Number of His+ revertants/plate: mean values of three triplicates, the assay was repeated two times 
S9- refers to assay without metabolic activation; S9+ refers to assay with metabolic activation 




Table 8: Continuation 
Number of His+ revertants 
   PET   DCM   EtOH  Water   
Plant species Plant parts µg/ml S9- S9+ S9- S9+ S9- S9+ S9- S9+ 
Ekebergia capensis Bark 5000 18.0±2.9 20.0±3.0 14.3±3.0 22.0±6.0 9.3±0.7 25.0±1.0 16.3±2.7 44.5±6.5 
  500 22.3±1.3 26.5±6.5 16.7±0.3 23.0±2.0 13.0±2.0 35.5±0.5 12.0±1.2 50.0±3.0 
  50 11.0±1.0 23.0±1.0 11.7±0.3 18.0±3.0 10.0±0.0 22.0±0.0 14.3±1.7 50.0±7.0 
           
Grewia occidentalis Root 5000 20.7±3.0 22.5±2.5 20.7±1.8 29.5±1.5 16.7±1.3 14.5±0.5 10.3±0.9 46.0±2.0 
  500 20.3±3.5 21.5±0.5 20.0±1.5 11.0±0.0 19.0±6.5 18.0±1.0 13.3±1.8 23.0±2.0 
  50 21.3±3.3 25.5±3.5 13.7±1.8 21.0±0.0 15.7±0.9 16.0±0.0 12.0±1.0 43.5±3.5 
           
Osyris lanceolata Leaf 5000 13.7±2.3 26.0±5.0 15.7±1.8 21.5±13.5 17.3±1.7 17.0±3.0 13.0±2.0 39.0±5.0 
  500 18.7±0.7 22.5±3.5 16.0±1.7 17.0±3.0 15.0±2.1 20.0±4.0 14.3±1.3 40.0±9.0 
  50 21.0±2.1 29.5±0.5 19.3±0.7 20.5±0.5 17.7±0.3 15.0±1.0 13.7±2.7 41.0±3.0 
           
Osyris lanceolata Root 5000 20.3±2.8 22.0±0.0 16.0±4.5 17.0±2.0 13.3±3.3 16.0±3.0 12.3±0.9 38.5±0.5 
  500 17.3±2.8 17.0±3.0 18.0±3.2 15.0±0.0 15.7±0.3 16. 0±4.0 14.3±1.2 46.5±5.5 
  50 21.3±2.3 15.0±2.0 15.0±1.2 21.5±0.5 13.0±0.0 18.0±2.0 13.3±2.0 42.5±0.5 
 
Number of His+ revertants/plate: mean values of three triplicates, the assay was repeated two times 
S9- refers to assay without metabolic activation; S9+ refers to assay with metabolic activation 




Table 8: Continuation 
Number of His+ revertants 
   PET   DCM   EtOH  Water   
Plant species Plant parts µg/ml S9- S9+ S9- S9+ S9- S9+ S9- S9+ 
Peltophorum africanum Bark 5000 21.7±4.7 25.0±3.0 12.3±1.3 24.0±5.0 18.0±2.3 22.5±1.5 14.3±0.7 44.5±2.5 
  500 15.7±1.5 18.5±1.5 11.0±0.0 16.0±1.0 16.7±2.4 39.0±3.0 16.0±3.1 48.0±3.0 
  50 17.3±3.3 23. 0±8.0 19.3±1.2 18.5±2.5 18.0±1.0 26.0±5.0 12.7±1.3 48.5±4.5 
  
         
Pterocarpus angolensis Leaf 5000 19.3±1.3 17.0±0.0 13.7±0.3 20. 0±2.0 18.7±3.8 24.5±0.5 10.7±1.3 36.0±1.0 
  500 19.0±3.2 20.0±4.0 13.7±2.3 22.5±1.5 14.0±0.0 39.0±6.0 12.0±0.6 45.5±1.5 
  50 16.0±2.1 29.0±1.0 15.0±1.0 21.0±1.0 16.0±2.0 35.0±2.0 20.0±0.0 34.5±5.5 
           
Pterocarpus angolensis Bark 5000 15.7±0.9 21.5±1.5 15.0±1.2 20.5±0.5 16.0±0.0 22.0±0.0 14.3±0.3 42.0±4.0 
  500 13.3±1.3 20.5±0.5 13.3±2.0 24.5±3.5 13.7±1.8 12. 0±0.0 8.7±0.3 30.0±3.0 
  50 18.7±1.5 20.5±0.5 13.0±1.7 23.0±0.0 19.3±1.3 30.5±2.5 12.0±0.0 36.0±4.0 
           
Pappea capensis Leaf 5000 16.7±1.7 20.5±2.5 15.3±0.9 21.5±3.5 10.0±2.1 21.0±1.0 16.0±2.0 31.5±4.5 
  500 16.7±1.7 18.5±4.5 12.7±1.3 23.0±0.0 16.7±1.2 20.0±6.0 12.0±0.0 38.5±8.5 
  50 17.3±2.3 19.0±2.0 23.0±2.5 23.0±2.0 17.0±1.5 26.0±8.0 18.0±3.0 46.0±5.0 
 
Number of His+ revertants/plate: mean values of three triplicates, the assay was repeated two times 
S9- refers to assay without metabolic activation; S9+ refers to assay with metabolic activation 




Table 8: Continuation 
Number of His+ revertants   
   PET  DCM  EtOH  Water  
Plant species Plant parts µg/ml S9- S9+ S9- S9+ S9- S9+ S9- S9+ 
Ximenia caffra Leaf 5000 19.0±3.6 22.0±1.0 16.3±2.3 22.5±0.5 12.7±0.9 21.0±1.0 13.3±0.9 47.0±3.0 
  500 17.7±3.8 22.0±2.0 12.7±1.7 22.0±2.0 12.3±2.2 24.0±0.0 10.7±0.3 26.0±4.0 
  50 20.7±1.2 23.0±1.0 17.3±0.7 22.5±2.5 18.7±3.2 27.5±0.5 12.7±1.8 42.5±3.5 
           
Ximenia caffra Root 5000 20.0±1.2 24.5±0.5 15.3±0.7 21.0±0.0 13.0±2.5 19.5±0.5 14.0±2.0 41.0±9.0 
  500 21.0±2.5 18.5±4.5 20.7±1.9 22.5±0.5 15.0±1.5 29.0 ±14.0 11.3±0.3 36.0±6.0 
  50 17.3±0.3 25.5±6.5 19.0±1.2 24.0±1.0 19.3±2.3 37.5±5.5 15.0±2.0 42.5±3.5 
4NQO  2 273.0±13.4     4NQO 288.0±13.0  
2-AA  2  396.3±13.4    2-AA  391.3±2.3 
Water (-ve cont)        Water (-ve cont) 19.3±1.9 24.3±3.3 
DMSO (-ve cont)   18.3±2.4 22.0±4.2    DMSO (-vecont)   
 
Number of His+ revertants/plate: mean values of three triplicates, the assay was repeated two times 
S9- refers to assay without metabolic activation; S9+ refers to assay with metabolic activation 





When it comes to the use of plants by humans, Vha-Venda people are vigilant as to 
what to use. For example, plants with milky latex, unpleasant smells and those that 
cause irritation to eyes or the nose when burnt as firewood are not used for 
medicinal purposes because they are considered poisonous (MABOGO, 1990). 
However, mutagenicity effects of plants are not easily noticeable in human health, 
but the long-term effect such as cancer can manifest. 
 
Results obtained from this study, support the safe usage of the selected medicinal 
plants by Vha-Venda people. However, some carcinogenic chemicals are biologically 
inactive unless they are metabolized to active forms. In this study mutagenic effect 
was observed after metabolic activation of water extracts of E. burkei roots and E. 
capensis bark. The rest of the plant extracts showed no mutagenic effects in both 
organic and inorganic extracts or the effect could be hidden due to antagonistic 
effect of other compounds contained in the extract. None of the plant extracts 
showed clear mutagenic effects when extracted with organic and inorganic solvents.  
 
According to VERSCHAEVE and VAN STADEN (2008) plants that show clear 
mutagenic properties should be considered as potentially unsafe and they require 
further testing before they can be recommended for use. However, mutagenicity can 
also be useful as an anticancer tool, because most anticancer drugs are mutagenic: 
for example the spindle-disturbing substances taxol and vinblastine. Mutagenic 
potential in plants can be considered interesting for therapeutic use and merit further 
in depth investigations of their pharmacological properties. These plants can be 
therefore being considered as potentially safe, but further in vivo testing is required 








CHAPTER 6: Isolation and Tentative Identification of an 
Active Compound from leaves of Ximenia caffra Sond 
(Olacaceae) 
 
6.1. Introduction  
 
Plants have formed the basis of sophisticated traditional medicinal practices that 
have been used for thousands of years (GURIB-FAKIM, 2006). Plant based 
medicines were initially dispensed in the form of crude drugs such as tinctures, teas, 
poultices, powders, and other herbal formulations (JACHAK and SAKLANI, 2007). 
The use of some plants as medicine has resulted in the isolation of active 
compounds. Today plants continue to provide us with new chemical entitities (lead 
molecules) for the development of drugs against various challenges, including 
cancer, HIV/AIDS, malaria, Alzheimer‘s disease, venereal disease and general pain 
(JACHAK and SAKLANI, 2007).  
 
6.1.1. Distribution and morphology of Ximenia caffra 
 
Ximenia caffra is a shrub or small tree which grow up to 6 m tall with a shapeless 
and untidy crown sparsely branched. Branches and twigs are armed with stout 
axillary spines and are glabrous or dense tomentose. Leaves are alternate, dark 
green, folded upwards along the midrib and margin entire. Flowers in axillary clusters 
are small and greenish white. Fruits are oval in shape, bright red and yellow with 
small white spots (VAN WYK et al., 2008).  
 
Ximenia caffra is a southern African species; distributed across Tanzania, Zambia, 
Zimbabwe, Botswana, Namibia, Mozambique and South Africa (CHIVANDI et al., 
2008). The tree is found in woodlands, grasslands and on rocky outcrops as well as 







Figure 5. Ximenia caffra Sond leaves. Inset shows the fruit of X. caffra (BALOYI and 
REYNOLDS, 2004) 
 
6.1.2. Traditional uses of Ximenia caffra 
 
Ximenia caffra has a wide spectrum of medicinal uses. It is used to treat different 
diseases by several tribes in southern Africa including the Zulu, Venda, Ndebele and 
Shona cultures. Roots, bark and leaves of this plant are used for numerous ailments, 
including infertility, venereal disease, abdominal pain, cramps, diarrhoea, 
rheumatism, fever, ancylostomiasis and wounds. Leaf infusions are used for both 
humans and animals as eye lotions. The root infusion is used as a cure for bilharzia. 
The powdered root is added to soup or beer and taken as an aphrodisiac. Porridge 
from root decoctions is eaten to treat nausea by pregnant women and the decoction 
is used during early stages of pregnancy to prevent the infant from being born 




The fruits are eaten fresh or dried (ROODT, 1998). The fruits are rich in vitamin C 
(27%) and have a high protein value (ROODT, 1998). The kernel is edible and is 
also used to make jam and jelly. The seed contains 65% of a yellow, viscous, non-
drying oil (CHIVANDI et al., 2008). The oil is used as biofuel in lamps and to soften 
leather clothing, leather boots and skirts (VENTER and VENTER, 1996; VAN WYK 
and GERICKE, 2003). Fruit juice is applied to septic sores and the pustules from 
chicken pox (VAN WYK et al., 2008). VAN WYK and GERICKE (2003) indicated 
that the seed contains tannins.  
 
6.1.3. Ethnopharmacology of Ximenia caffra 
 
Extracts from the plant are reported to possess antibacterial activity against 
Staphylococcus aureus, Vibro cholera, Shigella dysentery, Shigella sonnei, Shigella 
flexneri, Shigella boydii, Pseudomonas aeruginosa and Helicobacter pylori (FABRY 
et al., 1996; FABRY et al., 1998; MATHABE et al., 2006) as well as antifungal 
activity against Candida albicans (SAMIE et al., 2005). In Zambia and South Africa 
the plant is used to treat VDs (MABOGO, 1990; NDUBANI and HÖJER, 1999). 
Ximenia caffra contains simple phenolic compounds such as coumaric, vanillic and 
ferulic acids which have often been implicated in antibacterial activity (NDHLALA et 
al., 2008b). An unsaturated acid ximeninic acid has been isolated from the kernel oil 
(ROODT, 1998). 
 
This study was aimed at isolating and identifying active compounds using bioassay-











6.2. Materials and Methods 
 
Ximenia caffra leaves were collected and dried as described in Section 2.2.1., 
Chapter 2. Voucher specimen number Table 2 in Chapter 1. The dried powdered 
leaf material (500g) was extracted with 80% ethanol by sonication for 1h, and left 
overnight with constant stirring using a magnetic stirrer. The extract was filtered 
through a Büchner funnel and Whatman No.1 filter paper. The leaf residue was 
extracted further three times with 80% ethanol. The filtered extracts were combined 
and concentrated under vacuum using a rotary evaporator (Rotavapor-R, Büchi, 
Switzerland) at 30 °C. The weight of the dried residue was 54 g. 
 
6.2.1. Bioassay guided fractionation of aqueous ethanol extract of 
Ximenia caffra leaves 
 
Dried 80 % ethanolic extract was resuspended in 500 ml water: methanol (9:1) and 
was partitioned sequentially with hexane (500ml), dichloromethane (500ml) and ethyl 
acetate (500ml). The volume of aqueous fraction was reduced and re-diluted with 
water at each stage of extraction. The four fractions (hexane, DCM, ethyl acetate 
and aqueous) were dried using a rotary evaporator and subsequently assayed for 
antigonococal activity.  
 
6.2.2. Antigonococcal assay  
 
Gonococcal activity of the four fractions was determined by disc diffusion 
(RINGERTZ et al., 1991; PUTNAM et al., 1992) as described in Section 2.2.3.2., 
Chapter 2. Except that the fractions were resuspended in 80% ethanol to a 
concentration of 2 mg/ml. The dichloromethane fraction was the most active 52%. 
 
6.2.3. Gravity column chromatography 
 
The DCM fraction was further fractionated by gravity column chromatography (Merck 
9385 (silica gel), 130 g, 2.5 cm x 73 cm) using hexane: ethyl acetate (1:0 – 0:1) and 
subsequently ethyl acetate: methanol (1:0 – 0:1) step gradients. A fraction collector 
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(Gilson FC 203B) was used to collect fractions of approximately 10 ml each. These 
fractions were spotted onto TLC plate and developed in hexane: ethyl acetate (1:1). 
Fractions with similar TLC profiles were pooled together and then assayed for 
antigonococal activity (Fractions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12).  
 
6.2.4. Preparative Thin Layer Chromatography 
 
Fractions obtained after a repeated column chromatography were purified using 
preparative TLC (Merck glass plates, 20 x 20 cm, silica gel F254, and 0. 25 cm 
thickness), using hexane: ethyl acetate (1:1) as the solvent system about 34 mg of 
the most active fraction was applied to TLC. It yielded the active compound. The flow 
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Active, but not sufficient for compound identification  
 
Figure 6. Flow chart outlining the isolation procedure for antigonococcal compounds using 
dried X. caffra leaves. For NMR spectroscopy 81 was labelled RO-2 
 
6.2.5. Identification of Purified Active Compound 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) was performed at the School of 
Chemical and Physical Sciences, University of KwaZulu Natal, Pietermaritzburg, to 




Melting points (uncorrected) were measured on a Gallenkamp melting point 
apparatus. Optical rotations were determined on a Perkin-Elmer 241 polarimeter 
installed with a λ589 sodium lamp. IR spectra were measured on a Bio-Rad FTS-40 
series spectrometer in dry film. Electron impact mass spectroscopy (EIMS) were run 
on a Micromass Quattro Ultima spectrometer fitted with a direct injection probe (DIP) 
with ionization energy set at 70 eV and high resolution mass spectroscopy (HRMS) 
(EI) were performed with a Micromass Q-Tof Ultima spectrometer. 1H, 13C NMR, 
distortionless enhancement by polarization transfer (DEPT), correlation spectroscopy 
(COSY), nuclear Overhauser effect spectroscopy (NOESY), heteronuclear spin 
quantum correlation (HSQC) and heteronuclear multiple bond correlation (HMBC) 
spectra were recorded on a Bruker AV400 spectrometer in DMSO-d6, chemical shifts 
are reported in units of δ (ppm) and coupling constants (J) are expressed in Hz. 
Silica gel Merck KGaA (70–230 mesh) was used for CC and TLC silica gel 60 F254 
for analytical and preparative TLC (both Merck KGaA). Spots on chromatograms 
were detected under UV light (254 and 365 nm) and by Dragendorff‘s reagent stain. 
 
6.3. Results and Discussion 
 
6.3.1. Plant Extraction  
 
The dried and powered leaves (500g) of X. caffra yielded 54 g of crude extract. 
 
6.3.2. Bioassay-guided fraction for isolation of active compounds 
 
Hexane, DCM, ethyl acetate and aqueous results of four fractions from 80% ethanol 
extracts are presented in Table 9. The fractions considered to have good percentage 
inhibition ranged from 45-70%, 70-100% was considered as high activity. Out of the 









Table 9: Antigonococcal percentage inhibition of four fractions from liquid–liquid 
partitioning 
 
For the current study, these levels of activity were used: 0-44% not active; 45-70% 
moderate; 70-100% good activity. Values boldly-written are considered very active. 
 
6.3.3. Gravity-assisted Column Chromatography 
 
Gravity assisted column chromatography of the DCM fraction yielded 70 fractions. 
The fractions were pooled into 12 fractions based on similarity of TLC profiles and 
were subjected to antigonococcal activity assay. The results are presented in Table 
10.  Three out of the 12 fractions (5, 6 and 8) exhibited good activity against N. 













Fractions Percentage inhibition 
Hexane 44±0.00 
DCM 52±0.88 
Ethyl acetate 44±0.00 
Water 44±0.00 




Table 10: Antigonococcal inhibition percentage inhibition of fractions obtained 
following column chromatography 













Ciprofloxacin +ve control 1µg/disk (13.8±0.0 ) 100±00 
 
For the current study, these levels of activity were used: 0-44% not active; 45-70% 
moderate; 70-100% good activity. Values boldly-written are considered very active  
 
6.3.4. Preparative Thin Layer Chromatography 
 
Preparative TLC of Fraction 5 yielded 2 Fractions (51 and 52); 52 yielded 2 Fractions 
(52A and 52B). Fraction 6 yielded 1 Fraction (61) and Fraction 8 yielded 1 fraction 81. 
All these fractions exhibited good activity against N. gonorrhoeae, the results are 












Table 11: Antigonococcal percentage inhibition of fractions obtained from preparative 
thin layer chromatography  
Fractions Percentage inhibition 






Ciprofloxacin +ve control 1µg/disk (13.8±0.0 ) 100±00 
 
For the current study, these levels of activity were used: 0-44% not active; 45-70% 
moderate; 70-100% good activity. Values boldly-written are considered very active  
 
6.3.5. NMR Spectroscopy 
 
Because of insufficient amounts of fractions 51, 52, 52A, 52B and 61, only fraction 81 
was subjected to chemical elucidation. The 1HNMR, 13CNMR, COSY and HSQC 
spectrum of 81 are presented in Figures 6.1 to 6.5 
 
6.3.6. Spectroscopic data and some structural details for RO-2 
isolated from Ximenia caffra 
 
RO-2 (5.3 mg) was isolated as an amorphous gum from the ethanol extract of leaves 
of X. caffra. The structure of the compound has as yet not been ratified, but some 
details of its functional groups as well as its skeleton are provided via spectroscopic 
evidence as discussed below. Its 1HNMR and 13CNMR spectra Figures 7 and 8 in 
deuterated chloroform at 400 and 100 MHz respectively indicated that the compound 
was clean as evidenced by a high signal to noise ratio. Furthermore, all proton 
signals were concentrated in the  1-6 ppm region of the spectrum, excluding the 




The multiplet centred at  5.85 (3H) Figure 7 indicated the presence of three olefinic 
methine protons, which were seen to correlate to carbon signals Figure 8 at  
136.12, 129.37 and 127.30 as indicated by HSQC contour analysis Figure 11. 
Refinement of the multiplicity of these carbon signals as doublets was achieved via a 
DEPT experiment Figure 9. Further up field in the 1HNMR spectrum Figure 7, a one-
proton doublet of triplets at   4.41 (J = 11.6, 5.84 Hz) was assignable to an oxygen-
related methine proton, correspondent with a carbon doublet resonance at  68.37 
Figure 8. Also in the high field region of the 1HNMR spectrum, a methylene spin 
system was detected at  2.44 (1H, d, J = 17.16 Hz) and  2.24 (1H, d, J = 17.04 Hz) 
and confirmed by a single triplet resonance at  50.09 in the 13CNMR spectrum 
Figure 8.  
 
The remaining signals in the 1HNMR spectrum were attributable to four methyl 
groups [ 1.89 (3H, s); 1.30 (3H, dd, J = 6.4, 1.68 Hz); 1.07 (3H, s); 1.00 (3H, d, J = 
4.68 Hz)], which were correspondent with respective carbon signals at  19.20 (q), 
23.26 (q), 24.13 (q) and 24.41 (q). The most downfield-shifted of these at  1.89 (3H, 
s) was diagnostic for an acetate methyl group, and an acetate carbonyl singlet was 
visible at  162.89 in the 13CNMR spectrum. The remaining two signals in the carbon 
spectrum indicated the presence of an α,β-unsaturated ketone ( 198.19, s) and an 
oxygen-related quaternary carbon (  79.41), thus accounting for the thirteen carbon 
skeleton of RO-2.  
 
COSY analysis Figure 10 showed possible vicinal relationships for the following 
proton spin systems: a) olefin protons ( 5.85, 3H, m) with the oxygen-related 
methine proton ( 4.41, 1H, dt, J = 11.6, 5.84 Hz), methylene group proton ( 2.24, 
1H, d, J = 17.04 Hz) as well as one methyl ( 1.89, 3H, s); b) oxygen-related methine 
proton ( 4.41, 1H, dt, J = 11.6, 5.84 Hz) with the olefin protons ( 5.85, 3H, m) as 
well as to one methyl ( 1.30 (3H, dd, J = 6.4, 1.68 Hz); c) methylene group proton ( 
2.44, 1H, d, J = 17.16 Hz) with a single methyl group ( 1.07, 3H, s). 
 
In summary, the structure of RO-2 was seen to be composed of an α,β-unsaturated 
ketone, two double bonds, an oxygen-related methine proton (presumably derived 
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from an acetate group), an oxygen-related quaternary carbon, a methylene proton 
system, an acetate function as well as three methyl groups. 
 
The activity of the pure compounds is higher than that of the crude extracts, 
however, concentrations used for the pure compound was 2 mg/ml 25 times lower 
than 50 mg/ml of crude extracts. Therefore the activity of the isolated compound 
exhibited good percentage inhibition when compared to crude extracts and the more 
the compound was purified the more activity exhibited. N. gonorrhoeae develops 
resistance to most antimicrobial agents and the antibiotics recommended for 
treatment in some part of the world is now third-generation cephalosporins (WHO, 
2011).  
 
It is vital to search for natural inhibitors of N. gonorrhoeae before the organism 
become resistant to the cephalosporin. BELLO et al. 2011 reported the isolation of a 
compound (quercetin-3-O-rutinoside) from Pavetta crassipes leaves against N. 
gonorrhoeae. The reported results in this study represent another potential source of 
novel compounds from X. caffra leaves which can offer new effective treatment of 
gonorrhea. Although the active antigonococcal compounds of 51, 52,52A, 52B and 61 
was not sufficient for identification, the activity showed the existence of active 




In view of the above activity from the pure compounds it can be conclude that X. 
caffra leaves may harbour important compounds which may be used to overcome 
emergence resistance in N. gonorrhoeae. The antigonococcal active compounds in 
X. caffra support the use of the plant by traditional healers. However, mutagenic 
effects and more in vivo and in vitro confirmatory evaluate are required to test the 




























Figure 7. 1H NMR spectrum at 400.22472 MHz of antigonococcal compound isolated from 



































Figure 8. 13C spectrum at 100.645463 MHz of an tigonococcal compound isolated f rom X. 






















































































































Figure 11. HSQC spectrum of an tigonococcal compoun d isolated f rom X. caf fra leaves
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CHAPTER 7: General Conclusions  
 
Medicinal plants are used worldwide in order to overcome primary medical 
problems especially in rural areas. Medicinal plants are perceived as 
accessible, available, affordable, and safe for most people. They have gone a 
long way in providing unlimited and effective chemical compounds with a 
diverse range of pharmacological properties. Due to this, there is an increase 
in scientific research to identify and validate plant extracts that are potential as 
leads to new drug discovery to overcome limited supply and drug resistance 
challenges. 
 
In South Africa, 60% of the population consult traditional healers in preference 
to/or in addition to western doctors (VAN WYK et al., 2009). All cultures 
including, Vha-Venda people, have some definable plants that they use for 
food, medicine and ceremonies. In the Venda culture, traditional healers are 
regarded as the first line of health providers. Traditional healers are consulted 
regarding several conditions including healing, causes of diseases and/or to 
appease spirits or the deceased. In terms of VD diseases, Traditional 
Medicine is believed to be more effective than western medicine.  
 
Venereal diseases are amongst the fastest spreading infectious diseases 
worldwide (WHO, 2006). Venereal diseases are a major public health concern 
globally, causing an enormous burden of morbidity and mortality in both 
developing and developed countries (WHO, 2006). Venereal diseases also 
play a role in the transmission of the HIV virus. It is estimated that 11 million 
VD cases occur annually in South Africa (SONKO et al., 2003). The 
symptoms range from mild acute illness to painful lesions and psychological 
morbidity, for example following infection with N. gonorrhoeae.  
 
Untreated sexually transmitted bacterial infections results in life threatening 
conditions such as sterility, pelvic inflammation and ectopic pregnancies.  
Many antibiotics are available for the treatment of these microbial infections. 
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The problem is the resistance of these microbial agents against antibiotics. 
This is now a huge challenge in managing VD globally. 
 
Neisseria gonorrhoeae is the bacterium that causes gonorrhoea, one of the 
most widespread contagious infections in the world. The antibiotic resistance 
to this pathogen has increased rapidly in recent years and has reduced the 
options for treatment to the last line of treatment of using cephalosporin. 
However, cephalosporin has shown resistance in other countries (WHO, 
2011). This emergence of resistance in N. gonorrhoeae is likely to be followed 
by a rapid spread of the disease.  
 
Therefore there is a need to develop new antimicrobial agents with greater 
activity than those current available on the market. Medicinal plants have 
proven to be potential future sources of novel pharmaceutical compounds for 
the treatment of several diseases. In this case medicinal plants can be a 
second option for managing VD drug-resistant complications.  
 
This study was aimed at validating the use of medicinal plants that are used 
against venereal disease by Vha-Venda people and to identify active 
compounds in the extracts. Twelve medicinal plants used in traditional 
medicine against VDs by the Vha-Venda were evaluated for their 
pharmacological properties. The extracts were tested for their antigonococcal, 
antibacterial, antifungal properties and their ability to inhibit COX-1, COX-2 
and HIV-1 reverse transcriptase. The medicinal plants were also assayed for 
phytochemical composition to detect phenolic compounds including total 
phenolics, condensed tannins, hydrolysable tannins and flavonoids. The 
twelve medicinal plants were also tested for mutagenic effects. Furthermore, 
an active compound was isolated from active plant extracts and tested for its 
antigonococcal properties. 
 
Antigonococcal screening has shown potential in some of the selected 
medicinal plants against N. gonorrhoeae. This provides supporting evidence 
for the use of these plants in TM. Extracts of X. caffra roots and leaves, E. 
capensis leaves, B. speciosus stems and bark and O. lanceolata roots 
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exhibited promising activity against N. gonorrhoeae. Therefore these plants 
can be used in the treatment of VDs caused by N. gonorrhoeae. Water 
extracts were not active.  
 
Neisseria gonorrhoeae is associated with a variety of co-infections with other 
equally pathogenic strains such as B. subtilis, E. coli, K. pneumoniae and S. 
aureus. Thus, the selected plants were also tested for activity against these 
pathogens. B. speciosus bark, stems, E. capensis bark, E. burkei root, O. 
lanceolata roots, P. angolensis bark, P. capensis leaves, P. africanum bark 
and X. caffra leaves and roots exhibited good antibacterial activity against B. 
subtilis, E. coli and S. aureus with MIC values less than 0.1 mg/ml.  
 
The plants were also tested against C. albicans, an opportunistic pathogen 
that infects immunocompromised patients. DCM and EtOH extracts of B. 
speciosus leaves, bark and stems, E. capensis leaves, O. lanceolata roots, P. 
angolensis leaves, P. capensis leaves and X. caffra leaves exhibited good 
antifungal activity with MIC values less than 1 mg/ml.  No activity was 
observed against C. albicans in water and DCM extracts of A. chabaudii roots, 
G. occidentalis roots and A. digitata bark. 
 
Overall X. caffra and B. specious extracts exhibited the best antigonococcal, 
antibacterial and antifungal activities.  
 
The DCM and PE extracts of A. digitata bark, B. speciousus bark, P. 
angolensis bark and P. capensis leaves showed the best anti-inflammatory 
activity in both the COX-1 and 2 assays with inhibition above 70%. Based on 
the overall results, the COX-1 enzyme was inhibited more than the COX-2 
enzyme. Inhibition of COX-2 enzymes is associated with fewer side effects 
compared to inhibition of COX-1 enzyme.  
 
Apart from the cyclooxygenase (COX-1 and COX-2) enzymes, HIV-1 RT is 
also an important enzyme in VDs progression. The plants were evaluated for 
their inhibition properties against HIV-1 RT. The IC50 values of A. karroo bark, 
B. speciosus leaves, bark and stem, P. angolensis leaves, P. africanum bark, 
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P. capensis leaves, E. capensis bark, G. occidentails roots and A. digitata 
bark suggest activity of these extracts against RT. Overall, activities were 
moderate to high, except methanol extracts of A. chabaudii roots, E. capensis 
bark and O. lanceolata roots, which exhibited low inhibition percentages and 
higher IC50 values. The active plant extracts may therefore be used to 
slowdown the progression of HIV/ AIDS.  
 
Total phenolics, flavonoids, gallotannins and condensed tannins have been 
linked with several pharmacological activities including antibacterial, 
antifungal, anti-inflammation and enzyme inhibition. The plants contained 
different levels of phenolic compounds. The highest amounts of total 
phenolics, flavonoids, gallotannins and condensed tannins were detected in 
X. caffra leaves and roots. It was interesting to note that the same plants that 
showed good pharmacological activities were also rich in phenolic 
compounds. However, in some cases it was not so, for example B. speciosus 
showed good pharmacological activities but was low in flavonoids, 
gallotannins and condensed tannins. 
 
In order to test for safety, the Ames test using the S. typhimurium tester strain 
TA98, with and without S9 metabolic activation was performed for detection of 
mutagenic effects in the plant extracts. The results showed that all the plants 
were non-mutagenic toward S. typhimurium strains TA98 without metabolic 
activation. However, two plant extracts (E. burkei roots and E. capensis bark) 
showed mutagenic effects toward TA98 after S9 metabolic activation. Non-
mutagenic plant extracts can be considered safe upon further confirmation 
tests including in vivo studies.  
 
Based on the pharmacological activities observed here, plants may offer 
promising base information in the discovery of new drugs against gonorrhoea 
and possibly the management of related diseases. Ximenia caffra exhibited 
good activities in all bioassays. Therefore an attempt was made to isolate 
possible active compounds from the plant leaves. The isolated compound 
showed good activity against N. gonorrhoeae. However, the structure of the 
compound has as yet not been ratified. The activity of this compound may be 
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used as lead to overcome emergence resistance against N. gonorrhoeae and 
other VDs. 
 
The result obtained from this study goes a long way in validating the use of 
medicinal plants by Vha-Venda people against venereal and related diseases. 
The activities also show the importance of these plants in finding alternative 
effective treatment regimens for gonococcal infections.  
 
This research provided a basic understanding of efficacy of medicinal plants in 
traditional medicine and managing the challenge of VDs as well as improving 
human life. It also provides a platform as to which plants can be further 
exploited for various biological activities and bioactive compounds in 
pharmaceutical industries. This study will also contribute to sustainable 
utilization of these plant species for example X. caffra leaves can be used 
rather than roots. This study has further confirmed the need to screen these 
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